News Feed

Latest updates

Champion REIT Announces 2025 Interim Results

- Langham Place Mall marks 20 years of excellence "Stay Local, Trend Global", becoming a brand hotspot with Chiikawa Ramen Buta’s premier overseas debut- Three Garden Road successfully concluded all 2025 expirations with high retention rate- Langham Place Office Tower unveiled “6D Wellness” concept, an innovative concept strengthening its positioning as a one-stop wellness and lifestyle hub- Lower Hibor reduced interest expenses; all 2025 debt successfully refinancedHONG KONG, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - Champion Real Estate Investment Trust (stock code: 2778), the owner of Three Garden Road and Langham Place, announces its financial results for the six months ended 30 June 2025.Summary of financial results 1H 20251H 2024ChangeTotal Rental Income (HK$ million)1,0291,115- 7.6%Net Property Income (HK$ million)859954- 10.0%Distributable Income (HK$ million)476544- 12.6% Distribution per unit (HK$)0.07010.0809- 13.3% 30 Jun 202531 Dec 2024ChangeGross Value of Portfolio (HK$ million)58,09860,104- 3.3%Net Asset Value per unit (HK$)6.797.16- 5.2%Gearing Ratio24.5%23.7%+ 0.8ppOverviewWhile the global economy faced headwinds from trade tensions and geopolitical conflicts in the first half of 2025, Hong Kong’s market sentiment found support from several positive developments. A stock market revival, declining Hong Kong Interbank Offered Rates (“Hibor”) in the second quarter, stabilised residential sales and a steady tourism rebound helped counterbalance external pressures. However, persistent outbound travel by residents continued to divert spending elsewhere, weighing on local retail sales. Meanwhile, the office leasing market remained subdued, reflecting an ongoing imbalance between supply and demand. Against this backdrop, distributable income of the Trust decreased by 12.6% to HK$476 million and distribution per unit (“DPU”) declined by 13.3% to HK$0.0701.Ms. Christina Hau, Chief Executive Officer of Champion REIT (Left), Ms. Amy Luk, Investment and Investor Relations Director of Champion REIT (Right)Three Garden RoadAlthough overall office leasing momentum in Central remained suppressed, we received increased leasing inquiries amid rising financial market activities, with demand primarily from finance-related firms. Several new small-sized tenants, including family offices, committed to establishing operations in the property, while an existing banking sector tenant expanded its presence here. Occupancy of Three Garden Road office was 80.7% as at 30 June 2025. Rental income of the property fell 5.4% to HK$540 million (2024: HK$571 million). We advanced lease renewal efforts, successfully concluding all 2025 expirations with a high retention rate, including several anchor tenant renewals. For 2026, over 70% of the expiring leases have already been renewed.Langham Place Office TowerDuring the reporting period, Langham Place Office Tower launched “6D Wellness” YouTube channel to strengthen the property’s positioning as a one-stop wellness and lifestyle hub. As at 30 June 2025, lifestyle (wellness) tenants comprised 68% of the property’s tenant mix. Occupancy of Langham Place Office Tower remained stable at 86.9% as at 30 June 2025. The expanded co-working space introduced a Social Wellness Hall for wellness workshops and events, resonating with the property’s wellness positioning. Market rental continued to face challenges with rental income dropped by 9.1% to HK$151 million (2024: HK$166 million).Ms. Christina Hau, Chief Executive Officer of Champion REITLangham Place MallAs Langham Place Mall celebrates its 20th anniversary in 2025, it continues to embrace its bold “Stay Local, Trend Global” vision. Through immersive experiences and exclusive merchandise, we successfully attracted record crowds and drove sales, establishing new single-day footfall record in August. Recently, fashion brand BENLAI, marking its inaugural Hong Kong flagship presence in the mall, and Umbro’s first in town lifestyle themed pop-up store, have commenced operations. Further elevating the mall’s offerings, Chiikawa Ramen Buta has chosen this location for its premier overseas outlet, shortly becoming a hotspot since opening. Occupancy of Langham Place Mall remained high at 99.2% as at 30 June 2025, reaching full committed occupancy currently. Since changing consumer behaviour has posed challenges for tenants, rental income of the mall declined to HK$338 million (2024: HK$378 million).DistributionDistributable income of the Trust decreased by 12.6% to HK$476 million (2024: HK$544 million) and DPU declined by 13.3% to HK$0.0701 (2024: HK$0.0809). Based on the closing unit price of HK$2.08 recorded as at 30 June 2025, the total DPU represented an annualised distribution yield of 6.7%.Asset ValueThe appraised value of the Trust’s property portfolio was HK$58.1 billion as at 30 June 2025, declining by 3.3% from HK$60.1 billion as at 31 December 2024.SustainabilityWe continue to create shared values across our ecosystem through initiatives that drive climate resilience, build meaningful connections, and support community wellness. During the reporting period, we implemented an AI-powered chiller optimisation system at Three Garden Road, achieving 6.1% annual energy savings. Through our EcoChampion Pledge programme, we bring both office and retail tenants together in the shared commitment to fulfilling measurable environmental goals. Furthermore, Our Champion REIT ESG Gala, themed "Innovation - Inspiration · Integration", brought together over 1,000 tenants and business partners to advance sustainable operations and inclusive practices.OutlookAlthough Hong Kong retail sector has returned to growth and the financial market has rebounded, the overall operating environment of the Trust is expected to remain challenging in the rest of 2025. While lower HKD interest rates should reduce interest expenses, negative rental reversion will likely continue to suppress rental income and reduce distributions compared to last year. We remain committed to maintaining operational agility to navigate this competitive market landscape.About Champion REIT (stock code: 2778)Champion Real Estate Investment Trust is a trust formed to own and invest in income- producing office and retail properties. The Trust focuses on Grade A commercial properties in prime locations. It currently offers investors direct exposure to nearly 3 million sq. ft. of prime office and retail floor area. These include two Hong Kong landmark properties, Three Garden Road and Langham Place, as well as a joint venture stake in 66 Shoe Lane in Central London. The Trust has been awarded the top five-star rating by GRESB since 2023. Champion REIT is managed by Eagle Asset Management (CP) Limited, a member of the Great Eagle Group.Website: www.championreit.com Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-20

uSMART Group Accelerates Expansion with 12 New Branches

HONG KONG, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - uSMART Securities, a strategic investment of Chow Tai Fook (Holding) Limited, is pleased to announce the official launch of its new branches at Hong Kong’s Lok Ma Chau MTR Station and West Kowloon High-Speed Rail Station, strategically positioned to serve cross-border clients and passengers. A grand opening ceremony was held at the West Kowloon branch, attended by prominent financial professionals.At the event, Mr. Neo Lee, Executive Director of uSMART Securities, stated: "To provide more accessible financial services, uSMART Group plans to open 12 service centers across Hong Kong and Singapore this year, covering key districts such as Tsim Sha Tsui, Causeway Bay, Tsuen Wan, Sheung Shui, and Sheung Wan. This expansion will enhance our regional service network and bring us closer to our local clients."“As a No.1 Hong Kong Funded Fintech Brokerage^ with over 800,000 users globally, uSMART Securities is committed to elevating the investment experience. Our new branches offer comprehensive services, including investment consultations, account opening assistance, and personalized support for seniors and beginners to navigate our trading app," added Neo Lee.(From left to right: Business Development Director of uSMART Securities, Marketing Director of uSMART Securities, Executive Director of uSMART Securities, Head of Research and Asset Management of uSMART Securities and Business Development Manager of uSMART Securities)During the launch period, clients can enjoy exclusive mystery gift upon check in new shop, along with complimentary beverages, and mobile charging services. New customers who open an account at the branch will receive additional rewards. To further penetrate the Hong Kong market, uSMART Securities has introduced its "Trader Account", offering lifetime 0 commission for US and HK Stocks, plus 0 commission for US options trading for local clients.As a token of appreciation, uSMART Securities is rolling out a suite of 0 fee promotions for both new and existing clients, including:1)0% margin interest for IPO subscriptions | 0 handling fees for cash subscriptions2)0 commission & 0 platform fees for 100+ Hong Kong ETFs (covering high-dividend, virtual asset, and index ETFs)3)$0 cost to invest in US & HK stocks Monthly Investment Plan (no commission, platform fee, custody fee, and dividend collection fee)These offers are designed to support investors with different short, medium, and long-term investment strategies, ensuring all uSMART Securities clients could enjoy.Neo Lee also revealed that uSMART Group is actively expanding its teams in Hong Kong and Singapore to strengthen competitiveness. The Group’s newly established Manhattan office in New York will focus on serving hedge funds, family offices, and pre-IPO companies with institutional brokerage, asset allocation, and investment banking advisory services, reinforcing its leadership in fintech brokerage.Moving forward, uSMART Securities remains dedicated to customer-centric innovation, delivering premium offline services and cutting-edge financial solutions for global investors.^”No.1 Hong Kong Funded Fintech Brokerage" is based on TradeGo Cloud data, with uSMART Securities ranking first in monthly transaction volume among local Hong Kong-funded internet brokers for over a year as of May 2025.Terms and conditions apply.About uSMART:Strategic investments from Chow Tai Fook (Holding) Limited, uSMART Securities is a leading Hong Kong Funded Fintech Brokerage founded in 2018. Over the past seven years, it has pioneered the fusion of technology and finance, offering stocks trading, asset management, and wealth management solutions. Its proprietary platforms, uSMART HK APP and uSMART SG APP, operated by uSMART Securities (Hong Kong) and uSMART Securities (Singapore) respectively. It supports investments in Hong Kong stocks, US stocks, A-shares (Shanghai,Shenzhen,and Hong Kong stock connect), Singapore Stocks, Japan Stocks, UK Stocks, US options, ETFs, Funds, Bonds, Asset Management, Structured Notes, Futures, Crypto, Precious Metals, Gold, and forex. Furthermore, uSMART is equipped with a highly professional research and asset management team that offers asset management, wealth management, securities brokerage, institutional business, LPF services, and investment banking, dedicated to serving ultra-high-net-worth individuals and families, corporations, investment institutions, fund companies, and other brokerage firms with comprehensive asset management solutions.For details please visit: https://hk.usmartglobal.com/For any media queries, please contact:Carrie Wong9788 4665carriewong@usmart.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-20

CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers

SHENZHEN, CHINA, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company's exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth.According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements.“New Products” Strategy Drives Innovation Value Realization and Solidifies Growth MomentumAt the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value.To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio.Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth.Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option.CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects.Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional GrowthAccording to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets - International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model.Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential.In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market.Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-20

China BlueChem Reports Revenue of RMB5.850 Billion and Profit of RMB641 Million for 2025 Interim

Financial Highlights:(RMB Million)For the Six Months Ended 30 June1H 20251H 2024% ChangeRevenue5,8506,007- 2.61%Gross Profit8481,003- 15.45%Profit Before Tax839899-6.67%Net Profit Attributable to Owners of the Company641687- 6.70%Basic Earnings per Share (RMB)0.140.15- 6.67%HONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - China BlueChemical Ltd. (“China BlueChem” or the “Company,” stock code: 3983), China’s largest chemical fertilizer central enterprise in both production capacity and production volume, has announced its unaudited interim results for the six months ended 30 June 2025. In the first half of 2025, the Company realized a revenue of RMB 5.85 billion, slightly down by 2.6% year-on-yearly. Net profit attributable to owners of the Company amounted to RMB 641 million, a slight year-on-year decrease of 6.7%.Mr. RAO Shicai, CEO of China BlueChem said, “Despite the complex and volatile external environment and internal structural adjustment pressures, the Company’s key operating indicators have been successfully achieved. During the period, the Company has strengthened its safety production management, actively expanded its market and sales channels, and further developed lean management, while at the same time steadily implementing various measures to stabilize growth, reinforce reforms, and enhance efficiency Moreover, the Company has consistently adhered to a philosophy of green and sustainable development. Its methanol plant has been awarded the honorary title of “Energy Efficiency Leader” by the China Petroleum and Chemical Industry Federation for 14 consecutive years, and its synthetic ammonia plant has been awarded the honorary title of “Water Efficiency Leader” by the China Nitrogen Fertilizer Industry Association for 6 consecutive years. It also won the “2025 ESG Model Enterprise Award” at the 4th International Green Zero-Carbon Festival and ESG Leadership Summit, setting a benchmark for sustainable development brands.”In respect of production management, the Company continuously strengthened production and operation control and system management, thoroughly implementing the concept of green development and stable safety production conditions. During the period, methanol production at CNOOC Fudao and the cumulative throughput at Basuo Port both reached new highs for corresponding periods in history. The CNOOC Huahe Chemical Fertilizer Plant achieved 314 days of continuous operation, making a new record of itself and setting outstanding production indicators. In the first half of the year, the Company produced 968,000 tonnes of urea, 781,000 tonnes of methanol, 450,000 tonnes of phosphate fertilisers and compound fertilizers, and 132,000 tonnes of acrylonitrile series products.With regard to sales management, amidst the complex and ever-changing market situation, the Company has continued to further strengthen market analysis and keep up with the market to implementprecise pricing. By solidifying the weekly production and sales coordination meeting mechanism, the Company has optimised storage and transportation coordination, and ensured efficient product circulation., It has also comprehensively advanced market expansion and efficiency improvements. In the first half of the year, the Company sold 996,000 tonnes of urea, 726,000 tonnes of methanol; 386,000 tonnes of phosphate fertilizers and compound fertilizers, and 127,000 tonnes of acrylonitrile series products.As for green development, the Company accelerated the implementation of key projects, successfully producing the first tonne of green methanol in China using urban waste as raw material, and obtaining International Sustainability and Carbon Certification (ISCC) in the first half of the year. The green methanol has been successfully applied to domestically produced dual-fuel vessels, marking the first domestic use of green methanol. Furthermore, the Company achieved unified integration of monitoring data into the environmental protection information system, with pollutant emissions meeting standards at 100% for three consecutive years, and the number of environmental pollution incidents remaining at zero. The comprehensive utilization rate of phosphogypsum at DYK increased from 61.15% to 73.09%, exceeding the target requirements.Looking ahead to the second half of the year, urea will remain in a capacity expansion cycle and the overall market will continue to be oversupplied. In the third quarter, demand will be stronger driven by the combined impact of the export window and agricultural demand. Entering the fourth quarter, the release of new capacity and weakening demand will create a ripple effect, and prices are expected to remain under pressure. The prices of monoammonium phosphate may fluctuate within a narrow range at a high level, supported by strong raw material costs and favorable demand factors. The diammonium phosphate market is expected to maintain a stable consolidation cycle. In the third quarter, domestic autumn storage and export demand will resonate, resulting in strong overall demand and stable prices. In the fourth quarter, the demand for phosphate fertilizer is expected to decline overall, putting downward pressure on prices, but overall fluctuations will be relatively limited, supported by cost factors. In the second half of the year, the trend of methanol supply is expected to remain accommodative. Benefited from anti-involution in mainland China and the restriction policy on new coal-to-methanol projects, the supply and demand structure is expected to be improved. Downstream demand may see a phased recovery, with the overall market trend characterized by fluctuations. Regarding acrylonitrile, the oversupply situation will further intensify. Any improvement in acrylonitrile prices will require major domestic companies to reduce plant loads.Mr. RAO Shicai, CEO of China BlueChem said, “In the second half of 2025, the Company will refine its equipment management system to ensure safe and stable operation of facilities and establish a solid foundation for intrinsic safety. At the same time, it will focus on establishing its quality positioning, expanding market and sales, and enhancing marketing effectiveness. "AI+" initiatives will be promoted across the Company to accelerate the deep integration of digital technology and the real economy. In addition, the Company will push forward the study of key projects on the utilization of carbon-rich natural gas and strengthen communication matrix management to continuously enhance brand value.”About China BlueChemical Ltd.China BlueChemical Ltd. (“China BlueChem”) is a listed company that specialises in the development, production and sales of chemical fertilisers and synthetic chemical products. It is the largest Central enterprise in the field of chemical fertilisers in terms of both production capacity and production volume. The Company is a subsidiary of China National Offshore Oil Corporation which mainly engages in the exploration, development, production and sales of crude oil and natural gas. On 29 September 2006, China BlueChem was listed on the main board of The Stock Exchange of Hong Kong Limited with the stock code 3983. Currently, its production facilities are located in Hainan, Hubei and Heilongjiang, China, with a total designed annual production capacity of 1.84 million tonnes of urea, 1.3 million tonnes of phosphate and compound fertilisers (mono-ammonium phosphate, di-ammonium phosphate and compound fertiliser), 1.4 million tonnes of methanol, 200 thousand tonnes of acrylonitrile and 70 thousand tonnes MMA. It has a deep water port with a designed annual throughout capacity of 18.28 million tonnes in Dongfang city, Hainan province. Boasting continued growth of its brand value, the Company’s brand value reached historical high at RMB7.258 billion in 2025. Besides, the Company was awarded “ËSG Model Enterprise 2025” at the 4th International Green Zero-Carbon Festival Cum ESG Leaders Conference.For more information about the Company, please visit its website:www.chinabluechem.com.cn. Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-20

中海石油化學2025年中期實現收入人民幣58.50億元 盈利人民幣6.41億元

財務摘要(人民幣億元)截至 6 月 30日止年度2025年中期2024年中期變動收入58.5060.07- 2.61%毛利8.4810.03- 15.45%稅前利潤8.398.99-6.67%本公司擁有人應佔淨利潤6.416.87- 6.70%每股基本盈利 (人民幣元)0.140.15- 6.67% 香港,2025年8月19日 - (亞太商訊 via SeaPRwire.com) - 中海石油化學股份有限公司(「中海石油化學」或「公司」,股份編號:3983) 公佈截至2025年6月30日止日止半年度未經審計之業績。2025年上半年公司實現收入人民幣5,850百萬元,同比微跌2.6%,本公司擁有人權益應佔淨利潤為人民幣641百萬元,同比微跌6.7%。中海石油化學首席執行官饒仕才先生表示:「縱使面對外部環境複雜多變與內部結構調整壓力,公司主要經營指標仍然完成良好。期内,公司繼續強化安全生產管理,積極拓展市場與銷售渠道,深化精益管理;同時,扎實推進穩增長、深改革、提效能各項工作。此外,公司堅持秉持綠色可持續發展理念,甲醇裝置連續十四年獲評石化聯合會『能效領跑者』榮譽稱號,合成氨裝置連續六年蟬聯氮肥協會『水效領跑者』 榮譽稱號,並榮膺第四屆國際綠色零碳節暨ESG領袖峰會『2025 ESG 典範企業獎』,樹立了可持續發展品牌標杆。」生産管理方面,公司持續強化生產經營管控與體系管理,深入踐行綠色發展理念,安全生產形勢總體平穩。期内,海南富島甲醇產量與八所港累計吞吐量均創歷史同期新高,華鶴煤化工化肥裝置實現314天長週期運行,刷新自身紀錄,生產指標表現亮眼。上半年,公司生產尿素96.8萬噸、甲醇78.1萬噸、磷肥及複合肥45.0萬噸、丙烯腈系列產品13.2萬噸。銷售管理方面,面對複雜多變的市場形勢,公司持續深化市場研判,緊貼市場精準定價。通過固化產銷協同周例會機制,優化儲運銜接,保障產品高效流通。同時加大出口創效力度,全面推進拓市增效。上半年,公司銷售尿素99.6萬噸、甲醇72.6萬噸、磷肥及複合肥38.6萬噸、丙烯腈系列產品12.7萬噸。綠色發展方面,上半年公司加速推進重點項目落地,成功產出以城市垃圾為原料的國內首噸綠色甲醇,並獲得國際可持續發展和碳認證(ISCC)。該產品成功應用於國產雙燃料船舶,實現了國內綠色甲醇首次加注。此外,公司實現監測數據統一接入環保資訊系統,污染物排放連續三年100%達標,環保污染事故事件保持為零。其中,大峪口化工磷石膏綜合利用率由61.15%提升至73.09%,超額完成指標要求。展望2025下半年,尿素仍處於產能擴張週期,市場整體將延續「供大於求」格局,三季度受出口窗口期與農需支撐疊加影響,需求較強;進入四季度後,新增產能釋放與需求轉淡形成共振,價格預計持續承壓。磷酸一銨價格或呈高位窄幅震盪態勢,一方面原料成本支撐強勁,另一方面需求端亦有利好因素加持。磷酸二銨市場預計維持穩中整理節奏,三季度國內秋儲與出口需求共振,整體需求旺盛,價格將保持平穩運行;四季度磷肥需求預計整體回落,價格存在回調壓力,但受成本端支撐,整體波動幅度將較為有限。預計下半年,甲醇供應延續寬鬆態勢,受益於國內反內捲及煤製甲醇新建項目政策限制,供需結構有望改善,下游需求或呈階段性回暖,市場整體走勢以震盪為主。丙烯腈方面,供過於求的格局預計將進一步加劇,丙烯腈價格若要出現好轉,需依賴國內主流企業降低裝置負荷。公司首席執行官饒仕才先生表示:「2025年下半年,公司將聚焦完善設備管理體系,保障裝置安全平穩運行,夯實本質安全基礎;同時著力打造品質定位,抓好拓市拓銷,提升營銷創效能力。此外,公司將推進『人工智慧+』行動,加速數智技術與實體經濟的深度融合,推動富碳天然氣利用重點項目研究及強化傳播矩陣管理,持續提升品牌價值。」有關中海石油化學股份有限公司中海石油化學股份有限公司(「中海石油化學」)是專門從事化肥及相關化工産品開發、生産及銷售的上市企業,是化肥産能及産量最大的中央企業,為從事石油和天然氣勘探、開發、生産及銷售的中國海洋石油集團有限公司之子公司。中海石油化學於2006年9月29日在香港聯合交易所主板掛牌上市,股份編號:3983。公司現有生産設施位於中國海南、湖北及黑龍江,總設計年産能達184萬噸尿素、130萬噸磷複肥(磷酸一銨、磷酸二銨和複合肥)、140萬噸甲醇、20萬噸丙烯腈及7萬噸MMA,公司並擁有位於海南省東方市的設計年吞吐能力為1,828萬噸的深水港口。中海石油化學的企業品牌價值持續提升,2025年達72.58億元,創歷史新高。2025年,中海石油化學榮膺第四屆國際綠色零碳節暨ESG領袖峰會『2025 ESG 典範企業獎』。如欲查詢更多公司資料,請瀏覽公司網站 www.chinabluechem.com.cn。 Copyright 2025 亞太商訊 via SeaPRwire.com.

2025-08-19

Australian Breakthrough by Cholrem: Cyclodextrin Therapy Reverses Heart Disease, Hailed as Greatest Advance Since Statins

BRISBANE, AUS, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - Cholrem Pty Ltd, an Australian pharmaceutical research company, has published a landmark study in Cardiology Research and Cardiovascular Medicine, revealing that its proprietary cyclodextrin-based therapy Cavadex reverses atherosclerotic cardiovascular disease (ASCVD), the world's leading cause of death.Angiogram: Plaque Reduced Within 6 WeeksThe peer-reviewed case series demonstrates rapid symptom relief and significant regression of arterial plaque, marking a potential paradigm shift in heart disease treatment. The study followed 20 high-risk patients with advanced angina, with 18 (90%) reporting substantial symptom improvement (P0.0001) compared to expected outcomes. Objective imaging confirmed unprecedented results, including Coronary Artery Calcium (CAC) score reductions (e.g., from 591 to 521) and a 70% coronary artery blockage reduced to 27%. Cavadex, formulated with 2-hydroxypropyl-β-cyclodextrin (HPβCD), stimulates the body's natural vascular repair, offering a faster, more effective approach than existing therapies.The late Professor Laurie G. Howes, a renowned Australian cardiologist and study co-author, called Cavadex "the greatest pharmacological development in cardiology since statins." U.S. cardiologist Dr. James C. Roberts, who has treated hundreds with the therapy, noted, "We're seeing rapid, profound improvements in high-risk patients, with objective plaque regression and an excellent safety profile, leveraging a TGA- and FDA-approved molecule."Cholrem, founded by Kyle Hodgetts - a heart disease patient who pioneered Cavadex after conventional treatments failed - has supplied over 20,000 units globally. Despite HPβCD's non-patentable status limiting industry investment, Cholrem is driving this breakthrough forward. The company urges global medical communities to launch large-scale trials to validate these findings for millions suffering from heart disease.About Cholrem Pty Ltd: Cholrem is dedicated to advancing cyclodextrin-based therapies to combat ASCVD, the world's top killer, with a mission to deliver innovative, life-saving treatments. Cardiology Research and Cardiovascular Medicine Published Paper: https://www.gavinpublishers.com/article/view/cyclodextrin-therapy-for-atherosclerotic-cardiovascular-disease-a-case-series-on-plaque-regression-and-symptomatic-improvementRelated Videohttps://www.youtube.com/watch?v=5JqIanZxmuQContact InformationKyle HodgettsCholrem Pty Ltd Founder & CEOinfo@cholrem.com+61 424830574Related Videohttps://www.youtube.com/watch?v=5JqIanZxmuQSOURCE: Cholrem Pty Ltd Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-19

中國生物製藥(1177.HK)公佈2025中期業績

重點成果- 期內,集團共有2個創新產品獲中國國家藥品監督管理局(「NMPA」)批准上市,分別為普坦寧(美洛昔康注射液(II))和安啟新(注射用重組人凝血因子VIIa N01)。- 2025年上半年,集團創新產品收入達到人民幣78億元,同比增長27.2%。除創新產品外,集團還有5個仿製藥獲NMPA批准上市,整體仿製藥收入在2025年上半年保持正增長。- 截至2025年6月30日,集團共有37個腫瘤領域、7個肝病╱代謝領域、13個呼吸系統領域、和6個外科╱鎮痛領域的創新候選藥物處於臨床申請及以上開發階段。其中,2個腫瘤領域、1個外科╱鎮痛領域產品處在上市申請階段;11個腫瘤領域、1個肝病╱代謝領域、3個呼吸系統領域、1個外科╱鎮痛領域的創新候選藥物處於臨床III期;另有13個腫瘤領域、6個肝病╱代謝領域、12個呼吸系統領域、6個外科╱鎮痛領域的生物類似藥或仿製藥候選藥物處於臨床申請及以上開發階段。- 福可維(鹽酸安羅替尼膠囊)是一種新型小分子多靶點酪氨酸激酶抑制劑,目前已獲批9個適應症,另有3個適應症處於上市申請階段。此外,安羅替尼還有多項新適應症處於III期臨床研究階段,包括一線非鱗狀非小細胞肺癌、一線胰腺癌等,預計將在未來兩年逐步遞交上市申請。- 2023-2024年,集團共有5款腫瘤領域的國家1類創新藥獲批上市,分別為:億立舒(艾貝格司亭α注射液)、安得衛(貝莫蘇拜單抗注射液)、安柏尼(富馬酸安奈克替尼膠囊)、安洛晴(枸櫞酸依奉阿克膠囊)和安方甯(格索雷塞片);以及4款腫瘤領域的生物類似藥獲批上市,分別為:安倍斯(貝伐珠單抗注射液)、得利妥(利妥昔單抗注射液)、賽妥(注射用曲妥珠單抗)和帕樂坦(帕妥珠單抗注射液)。該等產品在2025年上半年快速放量,成為集團收入增長的重要貢獻品種。- 拉尼蘭諾(泛PPAR激動劑)是一種口服小分子藥物,用於治療代謝功能障礙相關脂肪性肝炎(MASH),目前正在全球開展III期臨床試驗,已完成全部受試者入組。2023年7月,拉尼蘭諾被藥品評審中心「CDE」納入突破性治療藥物程序。拉尼蘭諾是中國第一個進入臨床III期的MASH口服藥物,有望填補中國市場空白。- 天晴速暢(吸入用布地奈德混懸液)是中國首款獲批上市的布地奈德霧化劑型仿製藥,打破了國內市場長期被原研壟斷的局面,為國內氣道慢性炎症患者帶來了兼具有效性、安全性與經濟性的高端製劑產品。該產品已被納入集採範圍,集團及時採取了一系列主動管理措施,包括管道下沉、拓展市場覆蓋和集採外市場的二次開發。- 澤普思╱得百安(氟比洛芬凝膠貼膏)是中國首個獲批上市的國產凝膠貼膏,連續多年蟬聯外用鎮痛市場份額第一位。集團聚焦高潛力地區開發,深入拓展市場覆蓋,並逐步擴大產能以滿足市場的旺盛需求,推動澤普思/得百安銷售額持續快速增長。集團開發的第二代氟比洛芬貼劑預計將在一年內獲批上市。通過劑型升級,二代產品可顯著提高藥物透皮吸收度,增強貼膏粘附性,從而提升患者的依從性。香港,2025年8月18日 - (亞太商訊 via SeaPRwire.com) - 中國領先的創新研發驅動型醫藥集團-中國生物製藥有限公司(「中國生物製藥」或「公司」,連同附屬公司統稱「集團」)(股票編號:1177)公佈截至2025年6月30日止6個月(「期內」)之未經審核財務業績。回顧期內,集團收入同比增長10.7%至約175.7億元(人民幣,下同)。來自持續經營業務之歸屬於母公司持有者應佔盈利財務報表所示約33.9億元,同比增長約140.2%,基於歸屬於母公司持有者應佔盈利計算之每股盈利約18.82分。歸屬於母公司持有者盈利同比顯著增長主要受惠於本期間收入明顯增長及股息收益和投資公允價值變動收益明顯增長。歸屬於母公司持有者之基本溢利(非香港財務報告準則指標)約30.9億元,同比增長約101.1%。集團流動資金保持充裕,期內有計入流動資產之現金及銀行結餘約111億元、計入非流動資產之銀行存款約101億元,理財管理產品總額約92.9億元,資金儲備合共約304.9億元。董事會建議派發中期股息每股5港仙(2024上半年:3港仙)。銷售:研發創新動能強勁,多領域銷售成果持續放量集團一直以來重視研發,持續加大投入以提升研發質效,研發實力顯著增強,驅動銷售收入持續增長,成果豐碩。期內,抗腫瘤用藥之收入同比增加24.9%,達約66.9億元,佔集團收入約38.1%。外科/鎮痛用藥之收入同比增加20.2%,達約31.1億元,佔集團收入約17.7%。腫瘤領域,集團全面佈局非小細胞肺癌領域,覆蓋多種分型的全線治療,EGFR/cMet雙抗TQB2922即將啟動二線非小細胞肺癌III期臨床,EGFR/cMet雙抗ADC TQB6411 I期臨床正在入組,兩款產品進度均位於中國前列;深度佈局乳腺癌三大亞型, CDK2/4/6抑制劑庫莫西利膠囊有望成為HR+/HER2-乳腺癌的BIC療法,HER2雙抗ADC TQB2102較DS-8201潛在安全性優效,多個適應症正在同步拓展,其中三項乳腺癌III期快速推進;系統佈局消化道領域結直腸癌、胃癌、胰腺癌、肝癌等核心癌腫,LM-108(CCR8單抗)、TQB2868(PD-1/TGF-β雙功能融合蛋白)研發進度全球最快,且目前臨床數據展示出了極大潛力。於外科╱鎮痛領域,集團持續聚焦高潛力地區開發,深入拓展市場覆蓋,並逐步擴大產能以滿足市場的旺盛需求。期內,集團推動澤普思銷售額持續快速增長,而開發的第二代氟比洛芬貼劑預計將在一年內獲批上市。同時,2025年5月獲批的普坦寧憑藉長效鎮痛、安全性優異等優勢,有望成為該領域新的增長動力。研發:全力以赴推動創新產品開發,加大研發的資金投入於報告期內,集團共有2個創新產品獲NMPA批准上市,分別為普坦寧(美洛昔康注射液(II))和安啟新(注射用重組人凝血因數VIIa N01)。2025年上半年,集團創新產品收入達到人民幣78億元,同比增長27.2%。除創新產品外,集團還有5個仿製藥獲NMPA批准上市,整體仿製藥收入在2025年上半年保持正增長。一直以來,集團十分重視研發,不斷提升研發水平和速度,並視其為可持續發展的基礎,加大研發的資金投入。截至二零二五年六月三十日止六個月,研究與開發成本約人民幣318,756萬元,佔本集團收入約18.1%,連同已資本化的研發總開支出在內,約95.7%已計入損益表中。展望:深化創新與國際化布局,加速構建全球醫藥創新競爭力當前,中國醫藥產業正迎來歷史性發展機遇。在國家創新驅動發展戰略的指引下,我國生物醫藥創新能力顯著提升,創新藥研發已從「跟跑」逐步邁向「並跑」甚至「領跑」階段。中國創新藥不僅在本土市場構建起強勁的增長勢能,更在全球市場逐步嶄露頭角,日益獲得廣泛認可,已成為全球醫藥創新產業中不可替代的重要力量。作為行業領軍企業,集團深耕腫瘤、肝病╱代謝、呼吸系統及外科╱鎮痛四大核心治療領域,專注創新,服務病患,目標成為全球領先的製藥企業。集團深耕中國市場,同時將戰略視野投向全球市場,以國際化加速創新發展。同時,集團大力推進全球戰略合作佈局,通過商務拓展(BD)、戰略收購等多元合作路徑,快速充實創新管線儲備,強化核心技術平台。2025年7月,集團宣布全資收購禮新醫藥。禮新醫藥擁有全球領先的抗體發現和ADC技術平台,包括腫瘤微環境特异性抗體開發平台 (LM-TME™)、針對難成藥靶點的抗體開發平台(LM-Abs™),新一代抗體偶聯藥物平台(LM-ADC™)、以及免疫細胞銜接器平台(LM-TCE™)。此次收購將進一步增强集團的創新研發能力,加速集團的創新業務增長。此外,禮新醫藥卓越高效的研發團隊將加入集團,進一步强化集團的創新研發人才儲備,為持續產出高水平創新成果提供保障,助力創新生態的長遠發展。未來,本集團將繼續聚焦創新,提升四大治療領域的研發效率與質量,加快國際化步伐,力爭實現業務快速發展與業績穩步提升。有關中國生物製藥有限公司(股票編號:1177)中國生物製藥,連同其附屬公司,是中國領先的創新研究和研發驅動型醫藥集團,業務覆蓋醫藥研發平臺、智慧化生產和強大銷售體系全產業鏈。產品包括多種生物藥和化學藥,在腫瘤、肝病/代謝、呼吸系統、外科/鎮痛四大治療領域處於優勢地位。公司於2000年在香港聯交所上市,2013年入選MSCI全球標準指數之中國指數成分股;2018年入選恒生指數成分股;2020年入選恒生滬深港通生物科技50指數成分股、恒生中國(香港上市)25指數。中國生物製藥連續七年榮登美國權威雜誌《製藥經理人》發佈的「全球製藥企業TOP50」,連續三年獲評《福布斯》(亞洲) 「亞太最佳公司50強」。有關中國生物製藥的進一步資料,請瀏覽: www.sinobiopharm.com Copyright 2025 亞太商訊 via SeaPRwire.com.

2025-08-19

雙登股份宣佈於香港聯交所主板上市計劃

香港,2025年8月18日 - (亞太商訊 via SeaPRwire.com) - 全球領先的數據中心及通信基站儲能電池公司--雙登集團股份有限公司(股份代號:06960.HK)計劃將於香港聯合交易所有限公司(「香港聯交所」)主板上市H股股份。雙登股份將發售58,557,000股H股(視乎超額配股權行使與否而定),其中52,701,000股H股 (可予重新分配及視乎超額配股權行使與否而定)將作國際發售,合共佔初步發售股份總數的90%;餘下5,856,000股H股 (可予重新分配)將於香港作公開發售,合共佔初步發售股份總數的10%,每股價格爲14.51港元,另加1.0%經紀佣金、0.0027% 證監會交易徵費、0.00565%香港聯交所交易費及0.00015%會財局交易徵費(須於申請時以港元繳足,並可予退還)。雙登股份將於2025年8月18日(星期一)上午9時開始於香港公開發售,並於2025年8月21日(星期四)中午12時截止。雙登股份的股票預計將於2025年8月26日(星期二)於香港聯交所主板開始進行買賣,股份將按每手買賣單位500股H股買賣,股票代號爲06960.HK。中國國際金融香港證券有限公司、華泰金融控股(香港)有限公司、建銀國際金融有限公司為本次發行之聯席保薦人、保薦人兼整體協調人、整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人。基石投資者為三水創業投資有限公司,認購總額約合220百萬人民幣。全球領先的數據中心及通信基站儲能電池公司雙登股份於2011年於中國江蘇省泰州成立,是大數據及通信領域能源存儲業務的領先公司。憑藉對行業及客戶需求的深入理解,雙登股份開發行業領先的技術及安全性、成本效益及性能之間最佳平衡的多途徑產品,使公司能夠緊抓行業的巨大增長潛力。根據弗若斯特沙利文的數據,於2024年,雙登股份在全球通信及數據中心儲能電池供應商中出貨量排名第一,市佔率達11.1%。憑藉對提升品牌市場認可度的堅定承諾,雙登股份擁有高品質的全球客戶群,覆蓋接近30家全球百大通信運營商及設備製造商,與中國移動、中國電信、中國聯通、中國鐵塔等中國領先的通信運營商和通信設備製造商,如愛立信、沃達豐、法國電信、挪威電信等國際知名通信領域知名企業均建立了堅實的合作關係。此外,截至2024年12月31日,公司服務了中國十大自有數據中心企業的80%,以及中國十大第三方數據中心企業的 90%。強大的研發能力,打造安全性高、符合成本效益及性能優越的產品雙登股份的產品覆蓋了通信基站儲能、數據中心儲能、電力儲能等多元化應用場景。公司持續拓展鋰電池、鉛酸電池、鈉離子電池、固態電池等技術組合,確保能夠為各種應用情境和不同客戶匹配最合適的產品。雙登股份的研發聚焦於解決通信基站及數據中心的需求和痛點,並堅定致力於在安全、成本及性能方面不斷精進。雙登股份成立了以多名院士為首的30多位行業知名專家組成的技術專家委員會,與來自中國電力科研究學院、清華大學、南京大學、華中科技大學等領先機構的傑出專家合作。公司共同建立了長期穩定的科研合作機制,定期開展學術交流,及時掌握前沿的技術發展動向。通過積極開展產學研合作,雙登股份不斷優化產品工藝和技術,促進產品技術持續創新。截至2025年8月8日,雙登股份共擁有353項專利,其中發明專利111項。數據中心業務加速 成核心增長引擎隨著大數據技術的滲透與推廣,數據中心儲能電池成為保障資料安全及能源安全的必要產品。於2018年,雙登股份敏銳捕捉互聯網時代市場需求,並開始與大型科技企業、數據中心運營商等客戶建立合作關係。自2018年以來,公司陸續與阿里巴巴、京東、百度、萬國及秦淮數據等達成合作。於2022年,公司創新性在中國打造的首例規模化數據中心「備電+儲能」複合儲能項目,成功向雄安城市超算中心供應產品,助力其成功獲認可為國家綠色數據中心。截至2025年8月8日,雙登股份的數據儲能產品已累計應用於數百家數據中心。根據弗若斯特沙利文,於2024年,雙登股份在全球數據中心儲能市場的出貨量排名中國企業第一,在全球數據中心市場份額達到16.1%。截至2025年5月31日止五個月,雙登股份来自數據中心業務的收入由截至2024年5月31日止五個月的人民幣397.0百萬元增加近120%至人民幣872.9百萬元,收入占比從28.4%升至46.7%,成為公司第一大收入來源。得益于數據中心銷售收入增加,公司的总收入由截至2024年5月31日止五個月的人民幣1,394.2百萬元增加至截至2025年5月31日止五個月的人民幣1,866.6百萬元。經驗豐富以及前瞻遠矚的管理團隊雙登股份由一支高瞻遠矚、穩定並擁有豐富行業經驗的管理團隊領導。公司的董事長楊銳博士擁有豐富的儲能電池行業經驗和國際視野。彼獲得2024年儲能電池行業年度人物及江蘇省優秀企業家等多項榮譽。彼以極具前瞻性的戰略決策帶領公司持續創新和發展。雙登股份的執行董事兼副總裁楊寶峰博士擁有高級工程師職稱,榮獲江蘇省科技企業家及「雙創之星篇先進典型」等榮譽,擔任中國電池工業協會副理事長、中國化學與物理電源行業協會副理事長。高級管理團隊具備精深的儲能技術和經營管理的專業知識。所有高級管理團隊成員均已在公司任職多年,使得公司的管理協作更為行之有效,長期業務戰略更為統一。雙登集團股份有限公司董事會主席、執行董事及行政總裁楊銳博士表示:「作為全球領先的數據中心及通信基站儲能電池公司,我們始終堅持以客戶為中心,致力於為包括通信運營商及科技企業等客戶提供最適合、最優質的電池產品。隨著人工智能技術邁入普及應用的新紀元,其算力需求蓬勃增長將帶來電力能源需求的爆發式增長。面對算力需求持續擴大、數據中心能耗增長而帶來的需求,我們將保持創新,把握數據中心領域的發展機遇,打造我們的第二增長極。此外,我們还將繼續深化現有市場的佈局和滲透,同時擴大全球化佈局力度,進一步鞏固全球領先品牌地位。」所得款項用途假設超額配股權未獲行使,經扣除包銷費用及佣金(假設悉數支付酌情獎勵費用)及應付估計開支後,公司將自全球發售獲得所得款項淨額約756.3百萬港元,其中淨額約40%或約302.6百萬港元,預計將用作於東南亞興建一個鋰離子電池生產設施;約35%或約264.7百萬港元,擬用於建立研發中心;約15%或113.4百萬港元,擬用作加強海外銷售及營銷,以便能夠增強公司的全球影響力、更好地服務海外客戶並促進國際銷售;餘下約10%或75.6百萬港元,擬用作營運資金及其他一般企業用途。如有垂詢,請聯絡︰博達浩華國際財經傳訊集團馮嘉莉+852 3150 6763kelly.fung@h-advisors.global楊冬梅+86 15021840493may.yang@h-advisors.global Copyright 2025 亞太商訊 via SeaPRwire.com.

2025-08-19

Sino Biopharm (1177.HK) Announces 2025 Interim Results

Development Highlights- During the reporting period, the Group had two innovative products approved for marketing by the NMPA, namely Putanning (Meloxicam Injection (II)) and Anqixin (Recombinant Human Coagulation Factor VIIa N01 for Injection).- In the first half of 2025, the Group’s sales of innovative products reached RMB7.8 billion, a year-on-year increase of 27.2%. In addition to innovative products, the Group had 5 generic drugs approved for marketing by the NMPA. The overall revenue of generic drugs achieved positive growth in the first half of 2025.- As of 30 June 2025, the Group had a total of 37 innovative drug candidates in the field of oncology, 7 innovative drug candidates related to liver/metabolic diseases, 13 innovative drug candidates related to the respiratory, and 6 innovative drug candidates in the field of surgery/analgesia in the process of clinical trial application or above. Of these, 2 innovative oncology drug candidates and 1 innovative surgery/analgesia drug candidate are in the marketing application stage, and 11 innovative oncology drug candidates, 1 innovative liver/metabolic diseases drug candidate, 3 innovative respiratory system drug candidates, and 1 innovative surgery/analgesia drug candidate are in Phase III clinical trials. In addition, the Group had a total of 13 biosimilar or generic drug oncology candidates, 6 additional biosimilar or generic liver/metabolic diseases drug candidates, 12 biosimilar or generic respiratory system drug candidates, and 6 biosimilar or generic surgical/analgesic drug candidates in the clinical trial application or above.- Focus V (Anlotinib Hydrochloride Capsules) is a new type of small molecule multi-target tyrosine kinase inhibitor. It has been approved for nine indications, and three other indications are currently in the marketing application stage. In addition, Anlotinib has a number of new indications currently in Phase III clinical studies, including first-line non-squamous non-small cell lung cancer and first-line pancreatic cancer, with plans to gradually submit marketing applications within the next two years.- From 2023 to 2024, the Group obtained approval for and launched a total of five national category 1 innovative oncology drugs, namely, Yilishu (Efbemalenograstim alfa Injection), Andewei (Benmelstobart Injection), Anboni (Unecritinib Fumarate Capsules), Anluoqing (Envonalkib Citrate Capsules), and Anfangning (Garsorasib Tablets). It also obtained approval for and launched 4 oncology biosimilars, including Anbesi (Bevacizumab Injection), Delituo (Rituximab Injection), Saituo (Trastuzumab Injection), and Paletan (Pertuzumab Injection). The sales volume of these products accelerated rapidly in the first half of 2025, and they have become important contributors to the Group’s revenue growth.- Lanifibranor (pan-PPAR agonist) is an orally available small molecule drug that is currently undergoing Phase III clinical trials worldwide for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and enrollment of the patients in the global main cohort has been completed. In July 2023, Lanifibranor was granted Breakthrough Therapy Designation by the CDE. Lanifibranor is China’s first MASH drug to enter Phase III clinical trials and is expected to fill the gap in China’s MASH market.- Tianqing Suchang (Budesonide Suspension for Inhalation) is China’s first budesonide nebulized generic drug approved for marketing, breaking the long-term monopoly of branded drugs in the domestic market, and offering an effective, safe and economical high-end product for patients with chronic airway inflammation in China. The product has been included in the national VBP. The Group has taken a series of proactive management measures in a timely manner, including strengthening downstream channels, expanding market coverage and conducting secondary development in markets outside the scope of the VBP.- Zepolas/Debaian (Flurbiprofen Cataplasms) is the first domestically produced cataplasms approved for marketing in China, ranking first in the market share of topical analgesia for many years. The Group focuses on the development of high-potential areas, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand, driving the sustained rapid sales growth of Zepolas/Debaian. The second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing within one year. By upgrading the dosage form, the second-generation product can significantly improve the transdermal absorption of the drug and enhance the adhesiveness of the plaster, thereby improving patient compliance.HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX stock code:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2025 (the “Period”).During the Period, the Group recorded revenue of approximately RMB17.57 billion, a year-on-year increase of approximately 10.7%. Profit attributable to owners of the parent from continuing operations as reported was approximately RMB3.39 billion, a year-on-year increase of approximately 140.2%. Earnings per share attributable to owners of the parent were approximately RMB18.82 cents. The significant year-over-year increase in profit attributable to owners of the parent from continuing operations was mainly driven by the notable growth in revenue and significant increase in dividend income and fair value gain on investments during the Period. Underlying profit attributable to owners of the parent (non-HKFRSs measure) was approximately RMB3.09 billion, a YOY increase of approximately 101.1%. The Group's liquidity remains strong, with cash and bank balances classified as current assets of approximately RMB11.1 billion, bank deposits classified as non-current assets of approximately RMB10.1 billion, and wealth management products of approximately RMB9.29 billion in total, and total fund reserves amounting to approximately RMB30.49 billion at the end of the Period.The Board of Directors has recommended an interim dividend payment of HK5 cents per share (1H2024: HK3 cents).Sales: Strong momentum in R&D innovation with volume growth across multiple fieldsAlways placing utmost importance on research and development (“R&D”), the Group has consistently increased investments to enhance R&D quality and efficiency, which has led to a marked strengthening of R&D capabilities, driving sustained sales revenue growth and delivering substantial results. During the Period, sales of oncology drugs increased by 24.9% year-on-year to approximately RMB6.69 billion, accounting for approximately 38.1% of the Group's revenue. Sales of surgical/analgesic medications increased by 20.2% year-on-year to approximately RMB3.11 billion, accounting for approximately 17.7% of the Group's revenue.In the field of oncology, the Group has a comprehensive layout in non-small cell lung cancer (NSCLC), covering the full-line treatment of multiple subtypes. The EGFR/cMet bispecific antibody TQB2922 is about to initiate a Phase III clinical trial for second-line NSCLC, while the EGFR/cMet bispecific antibody ADC TQB6411 is currently enrolling patients for its Phase I trial, with both products progressing at the forefront in China. Also, the Group is deeply invested in the three major subtypes of breast cancer. The CDK2/4/6 inhibitor “Culmerciclib Capsule (TQB3616)” has the potential to become a best-in-class (BIC) therapy for HR+/HER2- breast cancer. The HER2 bispecific ADC TQB2102 demonstrates potentially superior safety compared to DS-8201, with multiple indications being explored simultaneously, including three breast cancer Phase III trials advancing rapidly. Additionally, the Group has systematically targeted key gastrointestinal cancers such as colorectal, gastric, pancreatic, and liver cancers. LM-108 (CCR8 monoclonal antibody) and TQB2868 (PD-1/TGF-β bifunctional fusion protein) are progressing at the fastest pace globally, with current clinical data showing significant potential.In the field of surgery/analgesia, the Group continuously focuses on the development of high-potential areas, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand. During the Period, the Group drove the sustained rapid sales growth of Zepolas, and the second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing within one year. Meanwhile, Putanning, which was approved in May 2025, is expected to become a new growth driver in this field due to its strengths, such as long-acting analgesia and excellent safety.R&D: Fully Committed to Advancing Innovative Product Development with Enhanced R&D InvestmentDuring the reporting period, the Group had two innovative products approved for marketing by the NMPA, namely Putanning (Meloxicam Injection (II)) and Anqixin (Recombinant Human Coagulation Factor VIIa N01 for Injection). In the first half of 2025, the Group’s sales of innovative products reached RMB7.8 billion, a year-on-year increase of 27.2%. In addition to innovative products, the Group had 5 generic drugs approved for marketing by the NMPA. The overall revenue of generic drugs achieved positive growth in the first half of 2025.The Group has always placed the utmost importance on R&D, continuously improving its R&D capabilities and speed. It considers R&D the foundation for its sustainable development and has continuously increased its investment in R&D. For the six months ended 30 June 2025, R&D costs amounted to approximately RMB3,187.56 million, representing approximately 18.1% of the Group’s revenue. Including capitalised R&D expenditure, approximately 95.7% was recognised in the statement of profit or loss.Prospect: Deepening Innovation and Global Expansion to Accelerate the Building of Global Pharmaceutical Innovation CompetitivenessChina’s pharmaceutical industry is currently embracing historic growth opportunities. With the national strategy of innovation-driven development as the guidance, the country’s biopharmaceutical innovation capabilities have witnessed significant enhancement, such that the R&D of innovative drugs has evolved from the positioning of the “passive mover” towards the “paralleled player,” or even the “market leader” on the global stage. Chinese innovative drugs not only gains strong momentum for growth in the domestic market, but also steadily makes their presence internationally, thus being widely recognized and becoming an indispensable impetus in the innovative pharmaceutical industry worldwide. As the industry leader, the Group remains deeply committed to four core therapeutic areas – oncology, liver/metabolic diseases, respiratory diseases, and surgery/analgesia. The Group aims to be a leading global pharmaceutical company through delivering innovative therapies for patients.While being firmly rooted in the Chinese market, the Group is expanding its strategic horizon to embrace global opportunities, and leveraging internationalization to accelerate its innovation and development. In the meantime, the Group is vigorously promoting its global strategic collaboration deployments through diversified approaches of collaborations such as business development (BD), strategic acquisitions, etc. In July 2025, the Group announced the full acquisition of LaNova Medicines. LaNova Medicines boasts world-leading antibody discovery and ADC technology platforms, including the Tumor Microenvironment Specific Antibody Development Platform (LM-TME™), the Targeted Antibody Discovery Platform (LM-Abs™), the New Generation ADC Platform (LM-ADC™), and the T-cell Engager Platform (LM-TCE™). The acquisition will further enhance the Group's innovative R&D capabilities and accelerate the growth of the Group's innovative business. In addition, the LaNova Medicines’ outstanding and efficient R&D team will join the Group to further strengthen its innovation and R&D talent pool, ensuring the sustained delivery of high-quality innovation outcomes, and supporting the long term development of the Group’s innovation ecosystem.Looking ahead, the Group will remain focused on innovation, while enhancing R&D efficiency and quality across its four major therapeutic areas. The Group will also accelerate its progress of internationalization, thereby striving for rapid business expansion alongside steady performance improvement.About Sino Biopharmaceutical Limited (HKEX:1177)Sino Biopharmaceutical Limited is a leading Chinese pharmaceutical company continuing to invest in Oncology, Liver/Metabolic Diseases, Respiratory and Surgery/Analgesia, exploring innovative therapies to improve the lives of patients. The company has strong manufacturing capabilities and broad patient access across China. Sino Biopharmaceutical Limited is committed to bring innovation to address unmet healthcare needs globally. The company was listed on the Hong Kong Stock Exchange in 2000, and was selected as a component of the MSCI Global Standard Index in China in 2013; In 2018, it was selected as a constituent stock of Hang Seng Index; In 2020, it was selected as a constituent stock of Hang Seng Stock Connect Biotech 50 Index and the Hang Seng China (Hong Kong Listed) 25 Index. The company has been listed in the “Top 50 Global Pharmaceutical Enterprises” published by the authoritative American magazine Pharmaceutical Manager for seven consecutive years, and has been rated as the “Top 50 Best Companies in Asia Pacific” by Forbes (Asia) for three consecutive years.For more information, please visit: www.sinobiopharm.com Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-19

Focus Graphite Announces Board Changes and Upcoming International Trade Mission with Natural Resources Canada

Susan Rohac, ICD.D, built one of Canada's largest and most active climate funds, overseeing a Pan-Canadian team of investment professionals and managed a portfolio over $1 billion in assets.Ottawa, Ontario--(ACN Newswire via SeaPRwire.com - August 18, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a leading Canadian graphite developer advancing high-grade projects in Québec, is pleased to announce the appointment of Mrs. Susan Rohac, ICD.D, to its Board of Directors, effective immediately. Mrs. Rohac replaces long-serving director Robin Dow, who has stepped down from the Board to focus on personal pursuits and other interests, and will continue to support a smooth transition.Susan Rohac had an extensive thirty-four (34) plus year career at the Business Development Bank of Canada ("BDC"), holding various leadership roles. Her final role was as Managing Partner of the Climate Tech venture capital fund, which she held from 2017 to May 2025. In this role, she oversaw a pan-Canadian team of investment professionals and managed a portfolio of over $1 billion in assets. This portfolio included a fully deployed $600 million fund I and a $500 million fund II launched in 2022 that focused on investing in Canada's most promising clean technology companies. Susan has invested in a diverse range of climate technologies across various sectors, including energy, mobility, built environment, carbon management, and industry & resource space, including advanced materials and critical minerals. In 2024, Susan was recognized as a Climate Leader by the Clean50 and received the Clean16 award. She holds undergraduate degrees in both science and finance and an executive MBA from the University of Ottawa. In 2024, she also obtained her ICD.D governance designation from the University of Toronto. Passionate about the environment and climate technologies, Susan currently sits on several governance and advisory boards and is actively involved with a few organizations that are aligned with her interests."We are delighted to welcome Susan to our Board," said Jeff York, Founder and Chairman of Focus Graphite. "She brings a strong track record in corporate finance and scaling industrial technologies, with a deep appreciation for Canada's critical minerals opportunity. Her experience and connections in the industry will be invaluable.""I am honored to join Focus Graphite at such an important moment," said Ms. Rohac. "The shift to green energy is driving unprecedented demand for secure supplies of critical minerals, and Canada has an opportunity to lead in building a reliable, sustainable graphite supply chain here at home. Beyond batteries, graphite is essential for advanced manufacturing and defense applications that underpin national security. I look forward to working with the team to help strengthen North America's self-sufficiency and reduce reliance on foreign supply."Mr. York added, "On behalf of the company and our shareholders, I want to thank Robin for his years of service and leadership. His guidance helped position Focus for its next phase of growth."Focus Graphite is also pleased to announce its participation in the Canadian Critical Minerals Investment Forum, an international trade mission organized by Natural Resources Canada and Invest in Canada. The event will be held in Tokyo, Japan from August 26-28, 2025, and in Korea from August 29-30, 2025. Focus Graphite is one of only two Canadian graphite companies attending the Forum, which brings together global investors, government officials, and industry leaders to advance critical minerals partnerships. In addition to the Forum, the Company will hold a series of bilateral meetings in both countries to further strategic discussions with potential partners and customers.On August 14th, 2025, Focus Graphite visited its Lac Knife project site near Fermont, Québec. The Company was pleased to host a representative from Korea Mine Rehabilitation and Mineral Resources Corporation ("KOMIR") alongside its newest board member, Susan Rohac. During the visit, Focus also met with officials from the Town of Fermont to provide a corporate and project update, highlighting recent progress and outlining the Company's pathway toward advancing Lac Knife to a fully permitted mining operation.In connection with Ms. Rohac's appointment, the Company has granted her 250,000 stock options pursuant to its Stock Option Plan. The options are exercisable at a price of $0.35 per common share and will expire on August 17, 2030. They are subject to the terms of the Plan as well as the policies of the TSX Venture Exchange.Image 1: Focus Graphite executives, IOS Geosciences, and a representative from KOMIR visit the Lac Knife project near Fermont, Québec, August 14, 2025To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/262819_1a756ef144f309ad_001full.jpgImage 2: Focus Graphite executives and IOS Geosciences visit with representatives from the Town of Fermont, QC, August 14, 2025To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/262819_1a756ef144f309ad_002full.jpgAbout Invest in CanadaInvest in Canada is Canada's foreign direct investment (FDI) attraction and promotion agency. We find the best to invest in Canada. This means working with our partners across the country and worldwide to attract global companies and support their expansion plans in Canada.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tétépisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comInvestors Contact: Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the advancement of the Lac Knife project through permitting and development activities, the Company's participation in the Canadian Critical Minerals Investment Forum in Japan and Korea and the potential outcomes of related bilateral meetings, the anticipated benefits of Ms. Rohac's appointment to the Board of Directors, the Company's ability to establish strategic partnerships and secure future customers, and its positioning as a near- and long-term supplier of specialty graphite materials within North America and globally.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262819 Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-19

Qunabox Group Deliver Strong H1 2025 Performance with Over 30% Growth in Revenue and Gross Profit

HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - In the first half of 2025, the artificial intelligence (AI) sector emerged as one of the most prominent structural investment themes in capital markets, sparking significant market enthusiasm. The market capitalization of leading companies in multiple AI-related segments saw significant increases, and the overall sector valuation rose markedly. As a result, the AI sector has become a high-prosperity track favored by institutional investors for portfolio allocation.Market analysts expect AI applications to emerge as a breakout sector as artificial intelligence deepens its integration across industries. Companies demonstrating both product innovation and real-world deployment capability are likely to draw heightened investor appetite. Among them, Qunabox Group (00917.HK), with its forward-looking strategic layout in “AI + Consumption Scenarios,” along with sustained high-intensity investment in technology and strong product commercialization capabilities, is poised to stand out in this wave of technology-scenario integration, potentially establishing itself as one of the most promising growth companies in this sector.On August 15, Qunabox Group released its 2025 interim results. In the first half of 2025, the Company achieved robust growth driven by continuous advancements in business model innovation, service capabilities enhancement, industry reputation building, and improved team execution. Leveraging its competitive advantages accumulated through years of sustained investment in AI, Qunabox Group seized the policy-driven opportunities in AI and consumption industries. The Company achieved revenue of RMB676.2 million, representing a year-on-year increase of 31.3%, while gross profit rose to RMB385.5 million, up 37.0% year-on-year, maintaining strong growth momentum and solidifying the Company’s leading position in China’s AI interactive marketing industry.Strategic Upgrade: Comprehensive Industrial Expansion from AI+ Marketing to AI+ Consumption ScenariosIn response to the profound transformation brought by the AI industrial revolution, Qunabox Group has fully upgraded its core strategy to focus on “AI + Consumption Scenarios”. The Company is concentrating on two key application scenarios – AI+ Marketing and AI+ Entertainment – while accelerating innovation in AI-powered services and product development. To support this strategic shift, the Company significantly increased its research and development investment in the first half of 2025 to RMB77.8 million, representing a year-on-year growth of 107.7%. As of 30 June 2025, Qunabox Group has established a robust technological moat, with cumulative registrations of 159 software copyrights and 34 patent applications.In terms of technology research and development, Qunabox Group has built an AI technology middle platform that reinforces its foundational technical architecture. By innovatively adopting a modular design approach, the Company has developed a reusable AI capabilities pool, significantly enhancing research and development efficiency and strengthening the scalability of its technologies across diverse application scenarios. Meanwhile, its self-developed multi-modal neural integrated collaborative engine—the AI-OMNI Engine (AI-Orchestrated Multimodal Neural Integration) —has achieved key technological breakthroughs, successfully empowering the three core layers of “perception, decision, execution,” significantly enhancing edge intelligence and multi-scenario adaptability.Notably, Qunabox Group has also made forward-looking advancements in the field of AI Agent. According to the Company’s 2025 interim report, it has deeply integrated AI Agent technology with its self-developed terminal operation and maintenance (O&M) large model, establishing a more intelligent O&M management system. This technological integration not only enables intelligent task dispatching and automated maintenance guidance, but also drives the transformation of O&M models from traditional “reactive maintenance” to “proactive prevention.” Industry analysts believe this move significantly enhances the professional capabilities and execution efficiency of terminal operation teams, marking a critical step in Qunabox Group’s journey toward operational intelligence. Moreover, it provides solid operational support for the large-scale implementation of the company’s “AI + Consumer Scenarios” strategy.Rapid Unleashing of the “AI+ Marketing” Business Flywheel EffectIn terms of marketing business, Qunabox Group has built a high-growth business flywheel by continuously driving the coordinated evolution of five core elements including product, client, data, technology and operations. In the first half of 2025, Qunabox Group’s marketing service revenue reached RMB568.0 million, representing a year-on-year increase of 37.9%; gross profit was RMB353.3 million, up 43.8% year on year. Among these, revenue from the standardized marketing services segment increased by 34.3% year on year, while revenue from the high-margin value-added marketing services segment grew by 63.1%, effectively boosting the Company’s overall profitability.On the one hand, while maintaining strong and stable partnerships with brand customers, Qunabox Group further tapped into the potential of KA customers by expanding service application scenarios, enriching and optimizing AI interactive marketing products, developing data strategy products, and refining its marketing product portfolio and service pattern, thereby broadening its collaboration with major customers. Leveraging its proprietary AI-OMNI Multi-modal Neural Synergy Engine, the Company has achieved dual breakthroughs in AI digital shopping assistants—enhancing both intelligent interaction capabilities and visual expressiveness—thereby significantly boosting customer engagement and conversion rates at offline terminals. In the first half of 2025, the average revenue per KA customer increased to RMB16.2 million, representing a year-on-year growth of 52.2%, providing strong support for high-quality revenue growth. On the other hand, by leveraging its technological and operational capabilities to advance the modularization of its marketing system, the Company enhanced its flexible combination capabilities between standardized marketing services and value-added marketing service modules, enabling complementary synergy, flexible integration, and efficient reuse between standardized and value-added services.It can be said that Qunabox Group’s “AI + Marketing” strategy has evolved from technological leadership to systematic growth, forging a five-dimensional moat integrating products, clients, data, technology, and operations—laying a robust foundation for sustained future growth.“AI+ Entertainment” Goes Global: Middle East Expansion Marks the Start of Ambitious Worldwide GrowthIn addition to marketing scenarios, Qunabox Group is actively capitalizing on the emerging “emotional consumption” trend in expanding the boundaries of AI entertainment applications. The Company has strategically positioned “AI + Entertainment” as a new frontier, aiming to build world-leading AI-powered indoor entertainment spaces, with the Middle East market as its first stop for global expansion. In the first half of 2025, Qunabox Group established an Overseas Entertainment Division, focusing on the strategic planning, product design, and commercialization of AI indoor entertainment spaces, to further strengthen the execution efficiency and market expansion of this business.Currently, the Division has completed its organizational structure and preparation for the first batch of venues, successfully obtaining the relevant local licenses. At the same time, core tasks such as product design and optimization, software and hardware system development, and the construction of content ecosystems are steadily progressing. Industry experts suggest this move may represent a strategic play in Qunabox Group’s global “IP incubation” initiative. By leveraging AI-generated technology and deep user behavior insights, the Company could develop original virtual characters and interactive experiences that balance local cultural relevance with global appeal. Through cross-media storytelling and digital asset management, these efforts may cultivate high-value original IPs. Such IPs are expected to serve as the core driver for AI entertainment spaces while extending into diverse monetization scenarios—including digital merchandise, brand collaborations, and fan engagement—significantly enhancing both user retention and commercial potential.In addition, Qunabox Group will deepen its diversification layout around the “AI + Consumption Scenarios” strategy. Through strategic acquisitions and ecosystem synergies, the Company will systematically extend its business boundaries and value chain depth to achieve high-quality, scalable growth.From a medium-to-long-term perspective, AI will continue to be the core driving force of industrial transformation, accelerating its penetration into marketing, entertainment, retail, and other scenarios. As a leading company in AI consumption scenarios, Qunabox Group remains at the forefront of AI industry applications through continuous strategic upgrades, technological innovation, and product implementation, building a long-term, sustainable, and high-quality growth flywheel. With the ongoing advancement of its “AI + Consumption Scenarios” strategy, Qunabox Group will unlock new frontiers for innovative growth. Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-19

The 35th Food Expo and concurrent fairs attract over 500,000 visits

- The Food Expo, Food Expo PRO, Hong Kong International Tea Fair, Beauty & Wellness Expo, and Home Delights Expo successfully concluded today, bringing together approximately 1,890 exhibitors and welcoming over 500,000 visits.- The per capital spending across the five fairs reached HK$1,630.- 48% of respondents believe that health, green and organic food trends are worth paying attention to. Halal food and beverage label at the expo helps promote the development of halal foods.- The five theme days, along with a series of exciting activities effectively boosted local consumption and created a bustling atmosphere.- The International Conference of the Modernization of Chinese Medicine and Health Products (ICMCM) featured 21 prominent speakers who shared innovative achievements and development trends in the globalisation of Chinese medicine.HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Organised by the Hong Kong Trade Development Council (HKTDC), the Food Expo, Beauty & Wellness Expo, and Home Delights Expo successfully concluded today. Food Expo PRO and the Hong Kong International Tea Fair, which opened to both industry professionals and the public for the first time, wrapped up successfully on 16 August. The five exhibitions featured some 1,890 exhibitors and attracted over 500,000 visits. The bustling atmosphere resulted in a per capita spending of HK$1,630, once again demonstrating the appeal of this annual event and the public’s purchasing power. Over at Food Expo PRO and the Hong Kong International Tea Fair, there were some 18,500 buyers from 64 countries and regions. Apart from Hong Kong, buyers came from Mainland China, Japan, Korea, Taiwan, as well as ASEAN countries, including Cambodia, Malaysia, the Philippines, Thailand, and Vietnam, among others, highlighting Hong Kong's significant role as a key food trade hub globally. Additionally, the International Conference of the Modernization of Chinese Medicine and Health Products, organised by the Modernized Chinese Medicine International Association (MCMIA) together with the HKTDC and ten scientific research institutions, also concluded successfully on 15 August.Sophia Chong, HKTDC Deputy Executive Director, stated: "This year, the event featured five major themes across several exhibitions, complemented by a variety of exciting activities that encouraged people to spend locally. The atmosphere was vibrant, fully reflecting the public's enthusiasm for gourmet food and trendy products. Due to weather conditions on the first day, the opening hours of the public fairs from Friday to Sunday were extended to provide exhibitors with greater opportunities to maximise sales and enhance visitor experiences. The Hong Kong International Tea Fair, which opened to the public over all three days for the first time, attracted significant attention and praise.”Despite challenges from sluggish trade in traditional markets and geopolitical challenges, the HKTDC has consistently focused on driving innovation, helping small and medium-sized enterprises seize global development trends, and creating opportunities through innovative and flexible thinking.Ms Chong added: “At this year's Food Expo and Food Expo PRO, we specifically curated products and services related to halal food, the silver economy, and food technology to meet emerging market demands and capture more business opportunities for exhibitors. We are pleased to see that the five exhibitions successfully generated more business for exhibitors, and the public enjoyed the culinary and shopping experience fully."Per capita spending reached HK$1,630; increased interest in halal foodsDuring the exhibition, the organisers conducted a random sampling survey, interviewing some 1,440 visitors. The per capita spending reached HK$1,630. Over 58% of respondents reported spending HK$1,000 or more at the exhibition, and over 30% indicated that their actual spending exceeded their original budget, demonstrating a strong and thriving consumption atmosphere during the event. The survey results also showed respondents believe that health, green and organic food (48%), and nutritional supplements (36%) trends are worth paying attention to. Among the respondents who are aware that the exhibition has a halal food and beverage label, more than half of the respondents (52%) believe it helps promote the development of halal foods.Vibrant consumption at the exhibition: encouraging sales performanceAs a highly anticipated annual event in the city, the Food Expo is dedicated to highlighting exquisite delicacies and fine wines from around the world. Director of exhibitor Yick Cheong Ho (HK) Limited, Joan Chui, stated that the Flavours of Intangible Cultural Heritage theme day has drawn extra interest and expected revenue of approximately HK$900,000. Some exhibitors are further expanding their business through the Food Expo. Huaying Lei, the chairman of Mayang Blue Phoenix Agricultural Development Co., Ltd from Mainland China stated that the company had signed a RMB60 million contract with a Hong Kong client for agri-products including high-quality edible eggs. Lei believed the Food Expo offers a perfect platform to showcase their wide-ranging products from Hunan Province.The concurrently held Beauty & Wellness Expo offered visitors a diverse range of premium products, with brand Mars, a Taiwan whey protein brand, the brand marketing manager Roy Wong said, “This year, the visitor traffic exceeded our expectations and we expect our on-site sales will increase by 30% to HK$200,000.”The Home Delights Expo showcased a variety of trendy household items and furniture. Andy Tsang, the design director of Renovation Guide Consultant Limited - specialising in interior design and decoration and participating in the expo for the first time - said, “Such a large number of new customers visiting our booth went above and beyond our expectations. We provided quotations to over 20 new clients, and we estimate that sales turnover will be around HK$2-3 million."Trade exhibitions expand business networks; thriving opportunities in halal foodThe 3rd Food Expo PRO and the 35th Food Expo introduced halal food and beverage label last year to help exhibitors expand their market for halal products. This year, more than 120 food suppliers showcased halal products from around the world, a 20% increase compared to last year. Daniel Chan, Director of Hong Kong exhibitor, Koon Chun Hing Kee Soy & Sauce Factory Ltd., said the company had seen many buyers from different countries and regions and discussed cooperations with five Mainland China and local distributors and restaurants and also met a buyer from Indonesia through the Click2Match platform.The new "Coffee" zone also debuted this year, showcasing coffee products, accessories, and machines from various origins. Jin Lu, Operations Director of CSFA Holdings Shanghai Co. Ltd., stated that the company has engaged with nine exhibitors from Mainland China, the U.S., South Korea, and other regions. The company is interested in placing a coffee beans order of approximately 50 metric tons (worth around RMB3 million) from a Yunnan-based supplier, as well as a RMB700,000 order for premium hairtail fish from a Korea exhibitor.The highlight zone, "Food Science and Technology," brought alternative and future food to the attention of professional buyers. My Care Healthcare Limited, a manufacturer of modified soft diet products for the elderly. Founder Francis Ho said they had discussions with nearly 120 buyers on the first day. On the last day of the fair, HKTDC arranged specialised medical industry buyer tours of which there were two potential buyers and the company is in talks with two hospitals to discuss the potential of supplying soft meals to them.The Okinawa Prefectural Government Hong Kong Representative Office organised four Okinawan companies to participate in the Food Expo PRO and successfully connected with buyers from Hong Kong, Mainland China, and international markets. Director Yasutoshi Nohara stated the fair helps them generate around HK$4 million in orders every year. Mr Nohara said the expo has been instrumental in providing them with a great opportunity, particularly to introduce Okinawan products in the Greater Bay Area and expand beyond Hong Kong with items that have not been shown in other markets before, such as soft shell turtle and Motobu beef.Sichuan Sentaiyuan Biotechnology Co., Ltd. has participated in the Food Expo PRO for four consecutive years, promoting healthy products. The company’s CEO, Liu Lei shared, “On the first day of the Expo, we met a long-time Hong Kong client in person for the first time, leading to a successful deal worth over US$5 million. The HKTDC also introduced several potential buyers from Japan, Singapore, and other regions and we expect deals to be finalised soon.” Mr Lei also mentioned that through the hktdc.com Sourcing platform, the company received around 30 inquiries before the expo and arranged on-site meetings with several clients. The “EXHIBITION+” hybrid model has significantly boosted the company’s visibility and secure more business opportunities.The Hong Kong International Tea Fair opened to trade and public visitors on all three days for the first time. Yip Wing-chi, Founder of exhibitor, Lock Cha Tea House, welcomed this arrangement and noted that there was a significant increase in traffic, creating a lively atmosphere. The public participation has effectively boosted business. Mr Yip said this year's sales were three times higher than last year.Hybrid model connecting local and overseas opportunitiesThis year, both Food Expo PRO and the Hong Kong International Tea Fair continued to adopt the EXHIBITION+ hybrid model, enabling global food and tea buyers to engage in business discussions through both physical exhibitions and online platforms. Until 23 August, exhibitors and buyers can still utilise the "Click2Match" smart matching platform for online discussion and to explore business opportunities.Chinese Medicine Conference Gathers Experts and Scholars to Promote Industry ExchangeThe International Conference of the Modernization of Chinese Medicine and Health Products, organised by the Modernized Chinese Medicine International Association in partnership with the HKTDC and ten scientific research institutions, has successfully concluded. The conference unveiled the latest professional information on traditional Chinese medicine and shared innovative achievements and development trends in the globalisation of Chinese medicine. Held concurrently with the Food Expo, Beauty & Wellness Expo, Home Delights Expo, Food Expo PRO, and the Hong Kong International Tea Fair, the event covered diverse fields such as food, beauty, health, home products, and Chinese medicine, successfully creating a synergistic effect, providing a broad platform for industry exchange.Photo download: http://bit.ly/4mrgT4SThe Food Expo, Home Delights Expo, and Beauty & Wellness Expo, three public exhibitions organised by the Hong Kong Trade Development Council, along with the Food Expo PRO and the Hong Kong International Tea Fair, have successfully concluded, attracting over 500,000 visits to attend and shopThe Food Expo PRO featured multiple pavilions showcasing unique culinary delights from different countries and regions, with exhibitors displaying halal food and beverage label gaining increasing attentionThe Federation of Hong Kong Industries and the Incorporated Trustees of the Islamic Community Fund of Hong Kong launched the “Hong Kong Q-Mark Halal Scheme” at the Food Expo PRO, announcing their joint efforts to promote halal certification and its development, fostering the sustainable development of halal products and culture in Hong KongAt the Food Expo PRO, the HKTDC signed a Memorandum of Understanding with The Bank of Saga Ltd., to promote businesses in Saga, Fukuoka, and Nagasaki to further their development in Hong Kong and beyond, revitalising both the local economy and prosperity of the regionThe Hong Kong International Tea Fair opened to the public for the first time over its three-day exhibition period, drawing many visitors to explore a variety of tea beveragesThe five major theme days ran throughout the exhibition period, with the opening day (14 August) featuring "Shall We Tea'”, focusing on demonstrations of Northern and Southern dim sum and creative dim sum making, tea therapy workshops and other exciting activitiesOn 15 August, “Flavours of Intangible Cultural Heritage” featured hands-on experiences in making traditional Hakka “hand-pulled” noodles, as well as introductions to intangible cultural heritage steamer and bamboo craftmanship culture, along with steamer craft demonstrationsOn 17 August, “Body, Mind & Soul” responds to the business opportunities brought by the silver economy, with exhibitors launching a variety of products and services tailored for seniorsThe Beauty & Wellness Expo has introduced a new Polish pavilion this year, showcasing high-quality products such as caviar essence cream, pure natural essential oils, hair growth serums, and other products. The newly-established "Scentsation" zone focuses on perfumes and aromatherapy, featuring over 20 participating brandsThe Home Delights Expo's "Avenue of Delights" brand zone included more than 35 exhibitors, showcasing various lifestyle brandsThroughout the exhibitions, a series of highly popular and exciting events were held, including "Star Chef Cooking Demonstrations”, "Smart Bidding", and lucky drawsThe International Conference of the Modernization of Chinese Medicine and Health Products presented the latest professional information on Chinese medicine. The conference, themed "The Latest Research Progress in the Prevention and Treatment of Tumours, Inflammation and Cardiovascular and Cerebrovascular Diseases with Traditional Medicine", featured 21 prominent speakers, including experts from Hong Kong, mainland China, and overseas, sharing innovative achievements and development trends in the globalization of Chinese medicineTo learn more about the opinions of exhibitors and buyers, please visit:HKTDC Food Expo PROfoodexpopro.hktdc.comHong Kong International Tea Fairhkteafair.hktdc.comHKTDC Food Expohkfoodexpo.hktdc.comHKTDC Beauty & Wellness Expohkbeautyexpo.hktdc.comHKTDC Home Delights Expohomedelights.hktdc.comThe International Conference of the Modernization of Chinese Medicine and Health Products (ICMCM)icmcm.hktdc.com Media EnquiriesOgilvy Public Relations:Rex CheukTel:(852) 5618 9908email: rex.cheuk@ogilvy.comLeanne PokTel:(852) 9379 9694 email: leanne.pok@ogilvy.comDaisy LeungTel:(852) 9275 7704email: daisy.leung@ogilvy.comHKTDC’s Communications and Public Affairs Department:Stanley SoTel:(852) 2584 4049email: stanley.hp.so@hktdc.orgSerena CheungTel:(852) 2584 4272email: serena.hm.cheung@hktdc.orgClayton LauwTel:(852) 2584 4472email: clayton.y.lauw@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong’s trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-18

Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC

HONG KONG, Aug 15, 2025 - (ACN Newswire via SeaPRwire.com) -?Everest Medicines today announced that etrasimod (VELSIPITY(R)) has been included in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults (the ?Updated Guidelines?). Etrasimod, an S1P receptor modulator, is recommended for the induction of remission in patients with moderately to severely active UC and for continuation in the maintenance of remission, compared with no treatment after induction of remission. Both recommendations are strong, with a moderate quality of evidence.This milestone underscores the high level of recognition from an internationally respected clinical guideline for the therapeutic value of etrasimod and highlights its potential to address the significant unmet medical needs of UC patients, offering a new treatment option worldwide.The updated guidelines were developed by the American College of Gastroenterology (ACG) including the latest evidence from the past five years. They provide a comprehensive summary of new approaches and advances in the treatment and prevention of complications in UC, with the goal of offering clinicians standardized and evidence-based recommendations to better manage patients with varying degrees of disease severity.The updated guidelines note that, etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P) 1,4,5 receptor modulator for the treatment of moderately to severely active UC. The S1P 1 receptor modulation regulates the trafficking of specific lymphocyte subsets out of the lymph nodes, leaving fewer peripheral immune cells available to traffic to sites of inflammation.The updated guidelines also reference the Phase III ELEVATE UC clinical study for etrasimod (ELEVATE UC 52 and ELEVATE UC 12). Both studies achieved all primary and key secondary efficacy endpoints, with a favorable safety profile consistent with previous studies of etrasimod. Etrasimod has been included in the AGA Living Clinical Practice Guideline on the pharmacological management of moderate-to-severe UC as one of the higher-efficacy medications suggested for first-line use in advanced therapy-na?ve patients.Prof. Wu Kaichun at the First Affiliated Hospital of AFMU who is the principal investigator for etrasimod?s Asia clinical trial said ?The updated guidelines further emphasize that achieving endoscopic mucosal healing to enable sustained, steroid-free remission is a core treatment goal for patients. This is not only critical for the long-term and safe management of the disease but is also closely tied to improving patients? quality of life. The strong recommendation of etrasimod for both induction and maintenance therapy in this population reflects the high level of recognition from an internationally authoritative medical authority.??The inclusion of etrasimod in the 2025 American College of Gastroenterology (ACG) Clinical Guideline for Adult Ulcerative Colitis, with a strong recommendation, is a clear recognition of its clinical efficacy and favorable safety profile. Mucosal healing is a recognized treatment goal in both domestic and international clinical guidelines for UC. Achieving mucosal healing at an early stage can significantly reduce the risk of disease relapse, hospitalization, colectomy, and the development of colorectal cancer.? said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. ?In Asia, the number of UC patients continues to rise, while treatment options remain limited, highlighting an urgent need for innovative therapies that balance efficacy, safety, and convenience. In China alone, the UC patient population was estimated at approximately 800,000 in 2024 and is projected to reach 1 million by 2030, placing an increasing burden on the healthcare system.?As a key innovative asset in Everest Medicines? autoimmune disease portfolio, etrasimod?s inclusion in the clinical guidelines underscores its global therapeutic potential as a new treatment option for UC patients across Asia, including in China. We remain committed to accelerating the regulatory approval process for etrasimod in Mainland China, South Korea, and other Asian markets to enhance patient access and help more individuals achieve higher-quality, longer-lasting disease remission.?As a core product of Everest Medicines, etrasimod has been approved in Singapore, Macao SAR, and Hong Kong SAR, and its NDA has been accepted in South Korea. In December 2024, China?s National Medical Products Administration (NMPA) officially accepted the NDA for VELSIPITY(R). As Everest?s third commercialized product, VELSIPITY(R) has been officially approved by the Guangdong Provincial Medical Products Administration for adult patients with moderately to severely active UC. It is now available at medical institutions designated under the Connect Policy in the Greater Bay Area. Additionally, Everest has launched a factory construction project at its Jiashan site to support local production of VELSIPITY(R). Everest Medecines Ltd, https://www.everestmedicines.com [HKEX: 01952] Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-18

勇奪12金14銀11銅 首程控股多家被投企業閃耀世界人形機器人運動會

香港,2025年8月18日 - (亞太商訊 via SeaPRwire.com) - 2025年8月17日,全球首個以人形機器人為核心參賽主體的大型綜合性賽事--世界人形機器人運動會,於北京國家速滑館「冰絲帶」圓滿落幕。本屆運動會由北京市人民政府、中央廣播電視總台、世界機器人合作組織、亞太機器人世界盃國際理事會等單位聯合主辦,共匯聚全球280支戰隊、超過500台機器人同場競技,全面展示具身智能機器人從技術突破到場景落地的完整產業鏈條。作為深度產業推動者,首程控股(0697.HK)所投企業整體表現亮眼,共計斬獲37枚獎牌(含金牌12枚、銀牌14枚、銅牌11枚),涵蓋各戰隊使用被投企業機器人本體參賽所獲獎項。與此同時,首程控股亦於「冰絲帶」外場設立面向公眾開放的「首程機器人科技體驗店」,成為本屆大會最受歡迎的科技互動展區之一。一、亮點企業集結亮相:宇樹科技:勇奪4金,並創下4.78m/s速度紀錄,G1平台支持隊伍再獲1金1銀1銅;北京人形機器人創新中心:展現「全自主執行」技術優勢,累計摘得2金6銀2銅;松延動力:橫掃自由體操、跳遠及舞蹈賽事,共奪2金1銀1銅,成為「科技×藝術」融合典範;銀河通用:凭藉全自主操控勇奪分揀技能競技冠軍,並協助高校戰隊包攬冠亚軍;星海圖:作為場景賽整機平台提供商,支持多所頂尖高校參賽,並助北京航天航空大學奪得季軍;加速進化:作為足球賽項技術平台提供方,為所有參賽隊提供機器人硬體與技術保障,成為「幕後冠軍」。二、打造機器人應用樣板:首程體驗店引領科技走入生活體驗店共展出超過200款智能產品,涵蓋家庭、教育、娛樂、醫療等多元場景,並將於2025年國慶黃金周正式落戶北京石景山・融石廣場,未來擴展至全國商圈、機場、高校等重點場域,開啟連鎖化推廣計劃。首程控股執委、聯席總裁葉芊表示:「我們希望通過真實場景的互動設計,讓大眾感受到機器人正從技術實驗室走向日常生活。」三、從實驗室走向真實應用,下一代生產力加速落地首程控股將持續依託「股權投資+資產運營」雙輪驅動戰略,攜手產業鏈合作夥伴推動具身智能機器人於教育、製造、醫療、城市運營等核心領域的產業化落地,釋放「下一代生產力」的巨大潛力。Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 亞太商訊 via SeaPRwire.com.

2025-08-18

Shoucheng Portfolio Wins 37 Medals at Humanoid Robot Games

HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - On August 17, 2025, the inaugural World Humanoid Robot Games—an international event centered on humanoid robots—concluded successfully at the National Speed Skating Oval in Beijing, also known as the “Ice Ribbon.”Co-hosted by the Beijing Municipal Government, China Media Group, the World Robot Cooperation Organization, and the Asia-Pacific RoboCup Council, the Games gathered 280 teams and over 500 robots from around the globe to compete across 26 disciplines, showcasing the full industrial chain from technological breakthroughs to real-world applications in embodied intelligence.As a key industrial accelerator, Shoucheng Holdings (0697.HK) saw several of its portfolio companies participate in major events, collectively winning 37 medals (12 gold, 14 silver, and 11 bronze), including awards where teams utilized robots built by Shoucheng’s portfolio firms. Simultaneously, Shoucheng launched the "Shoucheng Robot Tech Experience Store" adjacent to the venue, which became one of the most visited tech exhibits of the event.Highlights from Portfolio Companies:Unitree Robotics captured 4 gold medals and achieved a top speed of 4.78 m/s; G1-based teams earned an additional 1 gold, 1 silver, and 1 bronze;Beijing Humanoid Robot Innovation Center won 2 gold, 6 silver, and 2 bronze, representing the most advanced “fully autonomous execution” capabilities;Noetix Robotics earned 2 gold, 1 silver, and 1 bronze in gymnastics, long jump, and dance events, becoming a standout in “Tech × Art” integration;Galbot (by Galbot Technologies) secured the autonomous sorting championship and supported university teams that swept the podium;Galaxea-AI served as exclusive hardware provider in scene-based competitions and enabled a third-place finish by Beihang University;Booster Robotics powered all 3V3 and 5V5 football events, providing robot hardware and technical support, and was deemed the “backstage champion.”Robot Tech Experience Store: Bringing Innovation to the EverydayDuring the event, Shoucheng launched a pop-up “Robot Tech Experience Store,” featuring over 200 smart products across home, education, entertainment, healthcare, and wearables. The official store will open during China’s National Day Golden Week in October 2025 at Fusion Stone Plaza, Beijing, with nationwide expansion plans into airports, campuses, and commercial hubs.As Shoucheng’s Executive Director and Co-President Ye Qian stated: “Through interactive and relatable scenarios, we want the public to feel that robots are no longer distant technologies—they’re becoming part of daily life.”From Lab to Market: Accelerating the New Productive ForceWith a dual strategy of equity investment and asset operations, Shoucheng Holdings will continue to drive commercialization of humanoid and embodied robots in education, manufacturing, healthcare, and smart city operations, unlocking the full potential of the next-generation productivity paradigm.Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-18

RAK ICC Strengthens Foundations Regime with 2025 Legislative Enhancements

RAS AL KHAIMAH CITY, UAE, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Ras Al Khaimah International Corporate Centre (RAK ICC) has announced significant amendments to its Foundations Regulations 2019, which took effect on 31 July 2025. The changes represent one of the most substantial updates to the regime since its introduction, reinforcing the UAE's position as a competitive jurisdiction for wealth structuring and long-term asset protection.RAK ICC Foundations are widely recognized for their flexibility, confidentiality, and legal robustness, making them a preferred choice for high-net-worth individuals, entrepreneurs, and family offices, both within the UAE and internationally. These structures are commonly used for succession planning, family governance, and consolidating diverse assets under a single legal entity.The 2025 amendments introduce stronger legal safeguards and improved governance measures which include:Firewall Provisions - Stronger protection from foreign judgments conflicting with RAK ICC Regulations.Three-Year Statute of Limitations - Limits challenges to establishment or asset transfers to three years.Cause of Action Provisions - Creditor fraud claims are limited to the specific asset involved and only if rendering the founder insolvent.Duress and Officer Protections - Nullifies actions taken under foreign legal coercion, preserving internal governance autonomy of a foundation.Strengthened Arbitration Framework - Disputes can be resolved privately with court-level powers.Private Trustee Foundation Provisions - Clarifies asset segregation and fiduciary integrity for property held in trust by a foundation.Assets held within RAK ICC Foundation will now benefit from enhanced firewall provisions, ensuring that foreign judgments conflicting with UAE law cannot be enforced against them. A new three-year limitation period has been established for challenging the formation of a foundation or the transfer of assets into it, providing greater certainty for founders and beneficiaries. The reforms also tighten creditor protection rules by requiring proof of insolvency in fraudulent transfer claims, with liability capped at the value of the disputed asset to prevent overreach into unrelated holdings.In addition, the updated regulations address governance integrity and operational resilience. Officers of a foundation who receive foreign orders inconsistent with RAK ICC law are obligated to disregard them, thereby safeguarding the autonomy of the foundation's decision-making. The framework now explicitly confirms that assets held in trust by a foundation are legally distinct and separate from foundation property, ensuring clear asset segregation. Dispute resolution has also been strengthened, with arbitration provisions expanded to grant tribunals court-like powers, enabling disputes to be resolved efficiently, confidentially, and in line with international best practices.These changes are part of RAK ICC's broader strategy to maintain a forward-looking legal and regulatory environment that meets global standards while catering to the specific needs of its client base. They reflect the jurisdiction's commitment to supporting sophisticated wealth planning strategies that balance control, privacy, and long-term security.By enhancing its Foundations regime, RAK ICC is cementing its position in the UAE as a trusted partner for those seeking secure, adaptable, and internationally compliant solutions for wealth preservation and intergenerational planning.About RAK ICCRas Al Khaimah International Corporate Centre (RAK ICC) is a corporate registry based in Ras Al Khaimah, United Arab Emirates. The organisation provides international business companies and foundations, typically used for private and business structuring, asset consolidation, and succession planning. To date, RAK ICC has incorporated thousands of international companies and supports multi-billion dirhams in structured assets. It serves high-net-worth individuals, entrepreneurs, and businesses seeking flexible and secure solutions for long-term business and wealth management.For media enquiries, contact us at:Phone: +971 7 207 7177Email: info@rakicc.comWebsite: https://www.rakicc.com/contact-us/SOURCE: RAK ICC Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-17

WL Delicious Announced 2025 Interim Results

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Weilong Delicious Global Holdings Ltd (“WL Delicious” or the “Company”) and together with its subsidiaries (the “Group”) (Hong Kong stock code: 9985.HK) announced its unaudited interim results for the six months ended 30 June 2025 (the “Reporting Period”).RMBFor the 6 months ended 30 June20252024ChangeRevenue3,483 million2,939 million+18.5%Gross Profit1,642 million1,462 million+12.3%Gross Profit Margin47.2%49.8%-2.6p.p.Net Profit736 million621 million+18.5%Net Profit Margin21.1%21.1%Remain stableInterim Dividend0.18 / ordinary share0.16 / ordinary share+12.5%In the first half of 2025, despite global consumption growth facing general pressure, China remained one of the world’s largest consumer markets. Benefiting from the steady growth momentum of China’s snack food market in recent years, during the Reporting Period WL Delicious kept pace with industry development trends by adhering to its multi-category strategy, focusing on innovation, conducting in-depth consumer insights, accurately capturing market demand, and continuously strengthening its R&D capabilities, while further deepening brand penetration through approaches favored by young consumers, by creating multi-dimensional consumption scenarios and connections through various online and offline brand activities, the Group continuing to enhance its omnichannel coverage and sales network, thereby providing better services and experiences for clients and consumers.During the Reporting Period, WL Delicious' business strategy delivered substantial outcomes, with operational performance continuing to rise steadily, both revenue and net profit recording double-digit growth. In the first half of 2025, the Group achieved a total revenue of RMB3,483 million, representing a year-on-year growth of 18.5% primarily due to the Group’s continuous efforts in strengthening omni-channel development and brand building, as well as optimizing the channel structure during the reporting period. Despite the increase in certain raw material costs during the Reporting Period, which caused the Group's gross profit margin declined by 2.6 percentage points from 49.8% in the corresponding period of the Previous Year to 47.2%; gross profit still rose by 12.3% year-on-year to RMB 1,642.4 million, driven by both revenue growth and the Group’s active enhancement of supply chain efficiency. At the same time, benefiting from the increase in the Group's operating profit, net profit for the Reporting Period grew by 18.5% year-on-year to RMB 736.2 million, while the net profit margin remained at the same level year-on-year at 21.1%.Based on the overall performance during the Reporting Period, the Board of Directors has resolved to the distribution of the interim dividend of RMB0.18 per share, representing a payout ratio of approximately 60%. The dividend is expected to be paid on or about October 20, 2025.In terms of products, the Group adhered to a strategy of multiple categories, making efforts in terms of new products, new flavors, new craftmanship, and new packaging, such as expanding the boundaries of flavor innovation and responding in depth to consumers’ demand for innovative flavors. During the Reporting Period, the Group launched a number of new products such as sesame paste-flavored “Konjac Shuang” and spicy beef-flavored “Kiss Burn”, further expanding and enriching the product portfolio, enhancing product quality, meeting the diverse and personalized consumption needs of the market, and driving a stronger match between product strength and market demand.In terms of brand development, the Group continued to deepen brand penetration through approaches favoured by young consumers, building multi-dimensional consumer scenarios and connections through various online and offline brand activities. For example, the Group partnered with LINLEE to initiate the “Spicy Challenge”, leveraging its best-selling products and buzz to reach more consumers; collaborated with the domestic trend brand Crying Center to launch the “Big Kids Exclusive” series, using holiday marketing to evoke youthful taste memories. In addition, the Group officially announced Mr. WANG Anyu as the spokesperson for its Konjac products, leveraging the influence of celebrities to broaden the channels of communication. This series of measures effectively reached the young customer base and solidified the foundation for the brand’s youthful and fun-oriented development.In terms of distribution channels, the Group continued to advance its offline omni-channel and online all-platform coverage strategy. With the emergence of new channel market practice, the Group kept pace with channel changes, continuously expanding POS network, strengthening the sales team’s execution capability at the POS , collaborating with distributors to upgrade POS services and product availability, in order to drive steady growth in offline POS performance. On traditional e-commerce platforms, the Group also actively expanded its presence, building an all-platform ecosystem to ensure effective synergy with offline channels and to facilitate the implementation of its omni-channel development strategy.In addition, the Group has remained committed to automation upgrades and technological innovation breakthroughs in its production facilities, while accelerating the digital transformation of its business systems. On this basis, the Group has continuously strengthened organisational development and the building of its core talent pipeline, thereby enhancing overall operational efficiency and injecting strong momentum into the sustainable and steady development of its business.Mr. Liu Weiping, Chairman of WL Delicious, stated: "The Group will remain committed to its ‘multi-category’ product strategy, uphold product innovation, continue to strengthen brand building, and further reinforce WL Delicious’ brand image and distinctive positioning as youthful, fun, and creative. At the same time, the Group will actively embrace change, continuously enhance its omnichannel coverage capabilities, and provide consumers with more convenient consumption experiences. Looking ahead, the Group will embrace market changes with a more proactive mindset, continually enhance our competitiveness with better products, higher-quality services, and improved experiences, and create more value for consumers, customers, shareholders, investors, employees, and society as a whole."About Weilong Delicious Global Holdings LtdWEILONG Delicious Global Holdings Limited ("WL Delicious") is an all-in-one spicy snack products enterprise, leading in the research and development, production, and sales of spicy snack foods in China. Based on traditional formulas, WL Delicious started the Chinese seasoned flour products (also commonly known as Latiao industry, created our first Latiao snack in 2001, leading the standards construction of Latiao industry. With our outstanding product development capabilities, the Group has successfully diversified into vegetable products, bean-based products and others, including Konjac Shuang , Fengchi Kelp , XIAO MO NV and others. WL Delicious is a popular snack food brand among young consumers in China. It has an omni-channel sales and distribution network that effectively reaches young consumers. For more information, please visit: https://www.weilongshipin.com/. Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-17

Formerra Becomes North American Distributor for Syensqo PVDF

ROMEOVILLE, IL, Aug 12, 2025 - (ACN Newswire via SeaPRwire.com) - Formerra, a leader in performance materials distribution, has signed an agreement with Syensqo to distribute its Solef® Polyvinylidene Fluoride (PVDF) materials in North America. The agreement expands access to this critical material known for its combination of chemical resistance and flexibility. Solef® PVDF joins a growing list of high-performance materials in Formerra's portfolio designed to advance product development and innovation."With this new agreement, Formerra will be able to support customers across multiple markets with the materials they need to meet demanding application requirements," said Bob Long, Business Development Manager at Formerra. "In addition, this reinforces our commitment to delivering unmatched access, application support, and advanced materials for customers navigating complex performance and regulatory challenges."PVDF is positioned near the top of the performance pyramid for its outstanding chemical and heat resistance. Its inherent flexibility further enhances its suitability for demanding applications in chemical processing, healthcare, and automotive industries. Key properties* include:Heat resistance: Continuous use temperatures up to 150 degrees C (302 degrees F), bursting pressures of up to 139 bar (2,017 psi) at room temperatureChemical purity: Ultra-pure water resistivity, meeting SEMI F-57 specifications for the semiconductor industryBalance of strength and flexibility: Tensile yield strength up to 55 MPa (8,000 psi) with elongation at break up to 100%"We chose Formerra as our distribution partner for Solef® PVDF in North America because of their technical and commercial reach," said Rose Catherin, Sales Director Americas, Channel partners, Distribution and Digital Sales at Syensqo Specialty Polymers. "Their commitment to excellence and long-standing presence in critical markets make them an ideal fit to help expand the availability and use of Solef® PVDF."*As measured by TDSCaption: Formerra Becomes North American Distributor for Syensqo Solef®PVDF.Key Details:Formerra is an authorized distributor of Solef® PVDF from Syensqo in North America.The agreement includes support for high-performance applications across a broad spectrum of industries.PVDF offers excellent chemical resistance, thermal stability, and flexibility.Formerra provides technical guidance and supply chain expertise to support material selection and application development.About FormerraFormerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways - driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.Media ContactJackie MorrisMarketing Communications Manager, Formerrajackie.morris@formerra.com+1 630-972-3144SOURCE: Formerra Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-17

MMG Announces 2025 Interim Results, Profit, Earnings and Cash up on Strong Copper Growth

HONG KONG, Aug 12, 2025 - (ACN Newswire via SeaPRwire.com) - MMG Limited (“MMG”, stock code: 1208) has today announced its Interim Results with a net profit after tax of US$566.3 million. This represents more than a 600 per cent increase compared to a net profit after tax of US$79.5 million in the first half of 2024.The strong profit growth was primarily driven by increased copper production across all three copper mines, higher market prices for copper, gold, silver and zinc, as well as reduced unit costs at Las Bambas driven by higher copper production.“Over the first half of the year, our business delivered an outstanding operational and financial performance,” said Ivo Zhao, MMG’s CEO. “This result reflects the strength of our portfolio, the capability of our people, and the disciplined execution of our strategy.”Importantly, MMG’s safety performance improved with a total recordable injury frequency (TRIF) of 1.81 per million hours worked in the first half of 2025, an improvement compared to the full-year 2024 TRIF of 2.06. The significant events with energy exchange frequency (SEEEF) for the first half of 2025 remained consistent with the 2024 figure at 0.78 per million hours worked.Operationally, MMG achieved impressive copper sales and significantly improved production across all three of its copper assets, including a strong performance from Las Bambas and the ramp-up at Khoemacau and Kinsevere. Its Australian operations also maintained solid zinc production, despite navigating challenges including weather impacts, equipment reliability and lower grades due to mining sequence.Highlights include:Record first-half results for both EBITDA and EBIT, with EBITDA at US$1,539.9 million, representing a 98 per cent increase compared to the first half of 2024, and EBIT totalling US$1,058.8 million, an increase of 240 per cent over the same period.Net profit after tax was US$566.3 million, including a profit of US$340.0 million attributable to equity holders of the company.A 130 per cent increase in net cash flow from operations, totalling US$1,185.0 million, compared to the first half of 2024. This performance was mainly driven by increased copper sales and higher commodity prices.Balance sheet improvements, with record lows - since the acquisition of Las Bambas - in both net debt and gearing ratio. The Company’s net debt declined by US$903.3 million since the end of 2024, attributed to robust operational cash flow and the early repayment of US$500 million in Khoemacau Joint Venture Group borrowings. Gearing reduced from 41 per cent to 33 per cent over the first half of 2025.Record high total payable copper sales since 2018, reaching 237,651 tonnes in the first half of 2025.Las Bambas produced 210,637 tonnes of copper in copper concentrate in the first half of 2025, marking a 67 per cent increase compared to the same period in 2024. EBITDA reached a record high of US$1,310.5 million, representing a 122 per cent increase compared to the first half of 2024.“MMG’s balance sheet is in great shape – its strongest in 10 years - with debt reduction driven by higher profits and cash generation,” continued Mr Zhao. “Our ambition to become a top 10 global copper producer is within reach and we are well-positioned to achieve this through operational excellence, disciplined capital allocation, and a continued commitment to responsible mining.”Guidance for the year remains unchanged with total production aiming for a high end of 522,000 tonnes of copper and 240,000 tonnes of zinc. Las Bambas is expected to produce up to 400,000 tonnes of copper this year, assuming stable operating conditions and limited external disruptions. MMG is focussed on delivering its cost targets, with Las Bambas and Rosebery favourably adjusting their C1 cost range to reflect improved by-product credits and strong market conditions.The company is working to complete the recent Nickel Brazil acquisition and is confident in the long-term portfolio and growth contribution. MMG remains committed to supporting community development, strong local economies and employment and supplying the critical minerals the world needs for a sustainable future.Read the 2025 Interim Results announcement, watch a short CEO message and download company photos.About MMG Founded in 2009, MMG’s vision is to create a leading international mining company for a low carbon future. The company is headquartered in Melbourne, Australia and Beijing, China and listed on the Hong Kong Stock Exchange (HKEX1208). MMG’s portfolio supports copper, zinc and cobalt production, with soon to be nickel – products that are critical to achieving global decarbonisation and electrification targets. With operations in Australia, Botswana, the Democratic Republic of Congo and Latin America. More info here. Copyright 2025 ACN Newswire via SeaPRwire.com.

2025-08-17

艾曲莫德入選《2025 ACG臨床指南:成人潰瘍性結腸炎》,獲強烈推薦用於中重度潰瘍性結腸炎的誘導緩解及維持緩解治療

香港, 2025年8月15日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀今日宣布,旗下創新藥艾曲莫德(VELSIPITY(R),etrasimod)被納入《2025 ACG 臨床指南:成人潰瘍性結腸炎》(下稱「新版指南」),並獲得強烈推薦用於中重度活動性潰瘍性潰瘍性結腸炎(UC)患者的誘導緩解及維持緩解治療(中等質量證據)。新版指南同時建議,對於已通過鞘氨醇-1-磷酸(S1P)受體調節劑實現誘導緩解的患者,繼續使用艾曲莫德以維持緩解(強烈推薦,中等質量證據)。這一重要進展不僅體現了國際權威醫學指南對艾曲莫德臨床價值的高度認可,也進一步彰顯了其在滿足UC患者未被滿足的治療需求方面的潛力,為全球UC患者提供新的治療選擇。此次新版指南由美國胃腸病學會(American College of Gastroenterology,ACG)制定,基於近五年最新循證醫學證據,系統總結了UC治療及並發症預防的新方法與新進展,為臨床醫生提供規範、科學的管理參考,以更好地應對不同程度的UC患者治療需求。新版指南指出,艾曲莫德作為新一代高選擇性S1P受體調節劑,通過將活化的淋巴細胞滯留於淋巴結中,減少其在腸道中的浸潤,從而降低局部炎症反應,並伴隨外周循環淋巴細胞計數下降。艾曲莫德ELEVATE UC III 期注冊研究(ELEVATE UC 52和ELEVATE UC 12)這兩項隨機、雙盲、安慰劑對照研究均達到了所有主要和關鍵次要終點,分別在第12周和第52周顯著改善臨床緩解率,並實現持久的內鏡下深度黏膜愈合。值得注意的是,研究中100%的臨床緩解均為無激素緩解,安全性良好,與既往研究結果一致。指南也特意強調了與其他現有治療不同的是,艾曲莫德 ELEVATE UC III 期注冊研究中納入了潰瘍性直腸炎,且證實了在此類人群中顯著提升了臨床緩解率(治療12周時,43.2% vs 13.6%, p<0.001)。此前,艾曲莫德還被納入2024年美國胃腸病學協會(AGA)臨床實踐指南, 推薦作為潰瘍性結腸炎的一線治療。艾曲莫德亞太臨床試驗牽頭研究者、世界胃腸病學會司庫、亞太消化病學會副主席、中華醫學會第十屆消化病學分會副主任委員、中國人民解放軍第四軍醫大學附屬西京醫院吳開春教授表示:「新版指南進一步明確,『實現內鏡黏膜愈合以達成持續無激素緩解和避免住院手術』是中重度潰瘍性結腸炎治療的核心目標,這不僅關系到疾病的長期安全管理,也與改善患者生活質量息息相關。此次指南中,艾曲莫德被強烈推薦用於中重度活動性潰瘍性結腸炎的誘導和維持治療,標志著其臨床價值獲得了國際權威學術機構的高度認可,也為臨床實踐提供了全新的治療選擇。」雲頂新耀首席執行官羅永慶表示:「艾曲莫德此次獲新版指南強烈推薦用於中重度活動性潰瘍性結腸炎的誘導和維持治療,充分體現了其卓越的臨床療效和良好安全性,進一步確立了其作為一線治療新選擇的重要地位。新版指南明確將實現內鏡黏膜愈合作為治療中重度活動性潰瘍性結腸炎的核心目標,印證了黏膜愈合為國內外指南一致認定的重要終點,可顯著降低疾病複發、住院、結直腸切除及結直腸癌風險。值得一提的是,指南特別強調了艾曲莫德在潰瘍性直腸炎患者中同樣可顯著提升臨床緩解率。在亞洲,潰瘍性結腸炎患者人數持續上升,以中國為例,2024年中國的潰瘍性結腸炎患者數量約為80萬人,預計到2030年將達100萬人,現有臨床治療選擇有限,迫切需要兼顧療效、安全性與便利性的創新方案。我們將加速艾曲莫德的商業化進程,助力更多患者長期維持安全有效的疾病緩解,並提升生活質量。」作為雲頂新耀在自身免疫疾病領域布局的核心創新產品,艾曲莫德(維適平(R))的新藥上市申請已於2024年12月獲中國國家藥品監督管理局正式受理,預計今年年底或明年年初獲批。艾曲莫德已在新加坡、中國澳門和中國香港獲批,其新藥上市許可申請也已在韓國和中國台灣地區獲正式受理。艾曲莫德已被納入粵港澳大灣區內地9市臨床急需進口港澳藥品醫療器械目錄(2024年),在大灣區先行使用,成為雲頂新耀第三款商業化新藥。雲頂新耀已於2025年3月啟動艾曲莫德在嘉善工廠的本地化生產建設項目,支持其在大中華區及其他亞洲市場的供應及商業化落地。 Copyright 2025 亞太商訊 via SeaPRwire.com.

2025-08-16